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Obesity pandemic
 The World Health Organization (WHO) defines overweight and obesity as abnormal 
or excessive fat accumulation that presents a risk to human health (1). Currently, in 
population settings, obesity is defined by body mass index (BMI, calculated as weight in 
kilograms divided by the square of height in meters (kg/m2)), a simple measure of body 
fatness based on height and weight that applies to adult men and women. A BMI ≥25 kg/
m2 is categorized as overweight and a BMI > 30 kg/m2 is classified as obese (2). Recent 
findings indicate that BMI might not be considered as an accurate marker to define body fat 
distribution and cardiometabolic risk (3, 4). 
 Over the last decades, the prevalence of obesity worldwide has risen enormously 
and reached pandemic proportions. According to World Health Organization report in 
2018, about 39% of adults aged 18 years and over (39% of men and 40% of women) were 
overweight. Overall, about 13% of the world’s adult population (11% of men and 15% of 
women) were obese (1). According to a recent report based on data from the Organization 
for Economic Cooperation and Development (OECD) (5), obesity has reached epidemic 
proportions in both developed (USA (38.2%), UK (26.9%), The Netherlands (12.8%), and 
Japan (3.7%) ) and developing (Brazil (20.8%), China (7.0%), India (5.0%) and Indonesia 
(5.7%)) countries (6). Taken together, it is now clear that prevalence of obesity expands 
in all age groups  and in both sexes, irrespective of ethnicity, geographical locations and 
socioeconomic status (7). 
 Obesity is strongly associated with an increased risk of Type 2 Diabetes Mellitus 
(T2D), cardiovascular disease (e.g. dyslipidemia, stroke and hypertension), non-alcoholic fatty 
liver disease (NAFLD), musculoskeletal disorders, certain type of cancers and mental illness 
(8). Nowadays, not only the Western society is affected by obesity, also many low-middle-
income countries have increased morbidity and mortality rates because of the increasing 
prevalence of obesity (9). Furthermore, obesity and its co-morbidities are associated with 
increased healthcare costs (particularly secondary health care) and a reduced ability for 
employment, indicating high impact on social-economic burden (10). Thus obesity and its 
related co-morbidities have now been well-recognized as a major health problem, and the 
prevalence of obesity is predicted to still increase in upcoming years thereby having a large 
impact on future public health (6). 
Metabolic interorgan crosstalk in obesity and insulin resistance
 
 The underlying cause of overweight and obesity is an imbalance between 
energy intake and energy expenditure, which is influenced by genetic, microbial, neuro-
biological, behavioral, and environmental factors (11). Obesity is strongly associated with 
the development of insulin resistance which is defined as an impaired action of  insulin on 
its metabolic target organs such as adipose tissue (AT), liver, skeletal muscle and pancreas 
(12, 13). Figure 1 illustrates the inter-organ crosstalk between these tissues under obesity-
induced insulin resistant conditions.
 The adipose tissue is not only a passive fat storage organ, but is an active metabolic 
and endocrine organ (14, 15). The adipose tissue has two major functions in lipid metabolism, 
(1) to store lipid as triacylglycerol (TAG) from the uptake of meal-derived chylomicrons and 
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(2) the release of non-esterified fatty acids (NEFA) to supply energy into non-adipose tissue 
organs during conditions of increased energy demand (16). In the presence of a chronic 
positive energy balance, the fatty acid supply may exceed the storage capacity. This results 
in dysfunctional adipose tissue characterized by enlarged adipocytes (17, 18), an impaired 
differentiation of preadipocytes (i.e. adipogenesis) (19, 20), decreased adipose tissue 
blood flow (16, 21, 22), chronic low-grade local inflammation (23, 24) and an impaired 
lipid buffering capacity (25, 26). This impaired lipid buffering capacity is characterized by 
an reduced insulin-mediated TAG extraction and a reduced insulin-mediated inhibition 
of endogenous lipolysis. The impaired inhibition of endogenous lipolysis may be (partly) 
compensated by a relative increase in insulin secretion and thus increased circulating insulin 
concentrations (25).  If the AT buffering capacity is exceeded, fatty acids can spillover in the 
circulation and will be accumulated in other insulin sensitive tissues such as liver, skeletal 
muscle, and pancreas, which may relate to impairment in insulin sensitivity and insulin 
secretion (12, 13). Additionally, adipose tissue inflammation may result in systemic low 
grade inflammation, which has also been linked to the development of insulin resistance 
(27).
 In the liver, lipid accumulation may be explained by (i) an increased spillover of 
NEFA from subcutaneous adipose tissue (SAT) into circulation (28), (ii) an increased flux of 
FFA from visceral adipose tissue (VAT) through portal vein directing to the liver (“portal vein 
hypothesis”) (29), and (iii) an increased uptake from lipoprotein remnants (28). An increased 
lipogenesis due to an increased hepatic lipid supply leads to an increase of very-low-density-
lipoprotein (VLDL)-TAG secretion. Hepatic lipid accumulation interferes with insulin signaling 
in the liver, resulting in a diminished insulin-mediated suppression of VLDL production and 
secretion (26). Furthermore, hepatic insulin resistance is associated with an increased of 
endogenous glucose production and a reduced glycogen storage in the liver (30, 31).
 The skeletal muscle is an important organ in peripheral insulin sensitivity since it 
contributes to 70-90% of the total glucose disposal under postprandial conditions (26). An 
elevated lipid supply from adipose tissue and liver to circulation may result in an increased 
muscle lipid uptake. The obese, insulin resistant state is characterized by a reduced capacity 
to adapt fat oxidation to fatty acid supply (32). This leads to an increased intramuscular 
lipid accumulation, in particular the accumulation of bioactive lipid metabolites, which 
contributes to impairments in the insulin signalling (33, 34), a subsequent reduced glucose 
transporter-4 (GLUT-4) translocation to the skeletal muscle membrane (35), and a reduced 
insulin-mediated glucose uptake (36). 
 In pancreas, chronic exposure to elevated levels of NEFAs results in a decreased 
insulin gene expression and blunted glucose-stimulated insulin secretion (GSIS) in vitro 
(37). Using proton-magnetic resonance spectroscopy (1H-MRS), it has been demonstrated 
that pancreatic lipid accumulation was increased in individuals with an impaired glucose 
metabolism (38). This pancreatic fat accumulation may be associated with a decreased 
glucose-stimulated insulin secretion by the beta-cells (39).
 As a consequence, obesity-related insulin resistance accompanied by impairments 
in insulin secretion can be progressing towards a prediabetic state and subsequently toward 
T2DM (40). Prediabetes can be classified as a state of impaired fasting glucose (IFG, fasting 
glucose > 5.6 mmol/L) and/or impaired glucose tolerance (IGT, 2h oral glucose tolerance test 
OGTT)-derived glucose 7.8 – 11.0 mmol/L) (41, 42). These  two prediabetic states, may be 
representing different etiologies towards T2D (43).
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Figure 1. Inter-organ crosstalk in human obesity-related insulin resistance. Long-term positi ve energy balance results in systemic 
lipid overload and an increased lipid storage in the adipose ti ssue. When the buff ering capacity in the AT is diminished, fatt y acids 
(NEFA) spillover in non-adipose ti ssues such as liver, skeletal muscle, and pancreas. An impaired oxidati on of lipids in these ti ssues, 
directly to increase lipid accumulati on within these ti ssues and induce ti ssue-specifi c insulin resistance. Furthermore, cytokines 
pro-infl ammati on may also spillover from the AT towards other ti ssues and potenti ally decrease whole-body insulin sensiti vity. Of 
note, an increased of insulin secreti on has been suggested as an adapti ve response to whole-body insulin resistance at the early 
stage, and it decreases along with chronic insulin resistance and beta-cell dysfuncti on. (↑) increase; (↓) decrease. 
Measurement of insulin resistance
 
 There are several methodologies for esti mati ng insulin resistance. Homeostasis 
model assessment of insulin resistance (HOMA-IR) is a common-used surrogate marker 
describing glucose-insulin homeostasis by mathemati cally-derived nonlinear equati ons. 
It is derived from the use of the fasti ng insulin (FPI) and glucose (FPG) product, divided 
by a constant (22.5) (44). The HOMA-IR is a surrogate marker, which may refl ect merely 
hepati c insulin resistance (45). In additi on, Matsuda and DeFronzo have developed a model 
to esti mate whole-body insulin sensiti vity from the OGTT. Here the OGTT index of insulin 
sensiti vity [ISI (composite)] was calculated using both the data (insulin and glucose) during 
2-hours of the test (46). 
 Furthermore, Abdul-Ghani et al, has developed a model to esti mate hepati c insulin 
resistance and muscle insulin sensiti vity based on a multi ple sampling points OGTT. The 
hepati c insulin resistance index (HIRI) is esti mated using the square root of the product of 
the area under curves (AUCs) for glucose and insulin during the fi rst 30 min of the OGTT, 
where as muscle insulin sensiti vity index (MISI) can be esti mated using the rate of decay of 
plasma glucose concentrati on during the OGTT (47). Among the tools to determine IR and 
measure whole-body insulin sensiti vity, the hyperinsulinemic euglycemic clamp technique 
is recognized as the gold-standard method to esti mate insulin sensiti vity (44). In a two step 
of hyperinsulinemic euglycemic clamp with a [6,6-2H2]-glucose tracer infusion both hepati c 
and peripheral insulin sensiti vity as well as adipose ti ssue insulin sensiti vity can be assessed 
(48, 49). 
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Obesity, insulin resistance and vitamin D status
 Skin synthesis of vitamin D3 stimulated by sun exposure is the major source of 
vitamin D in humans. Vitamin D can also be ingested from the diet as vitamin D2 and D3 
(50). In form vitamin D2 is commonly found in mushroom (51), whereas vitamin D3 can be 
found in oil-rich fish and eggs, meat, fortified foods (most often milk and dairy products, 
margarine and spreads and some breakfast cereals), as well as supplementation (50, 52). 
The circulating vitamin D 25-hydroxyvitamin D3 [25(OH)D3/calcifediol) is still inactive until 
this has been hydroxylated (1-α-hydroxylase enzyme/CYP27B1) into 1,25-dihydroxyvitamin 
D/1,25OH2D3 (calcitriol) in the kidney, which is the active vitamin D metabolite (53). Both of 
the active and inactive form of vitamin D have been shown to be lipophilic as indicated by 
recent studies which were able to detect both vitamin D metabolites in adipose tissue (54, 
55). Vitamin D deficiency (defined as having [25(OH)D3] levels <50 nmol/L or <20 ng/mL) 
(56) often seen in human obesity across age, ethnicity and geographical locations (57). 
Vitamin D: skeletal function vs. extra-skeletal role in glucose and lipid 
metabolism
 
 The causal role of vitamin D deficiency in bone health is well established. Vitamin 
D sufficiency is pivotal for normal skeletal development from utero until childhood, and also 
for maintaining bone health in adults (58). This is due to the fact that sufficient of vitamin 
D levels lead to adequate calcium-phosphorus concentrations resulting in an effective bone 
mineralization to prevent vitamin D deficiency  and related diseases like rickets (59). In 
adults, low 25(OH)D3 and high Parathyroid hormone (PTH) also lead to low serum calcium 
and phosphorus concentrations, resulting in osteomalacia, i.e., a defective mineralization of 
the collagen matrix causing a reduction of structural support and being associated with an 
increased risk of fracture (58). 
 During the last couple decades, studies suggest the link between vitamin D 
and chronic metabolic diseases or conditions like obesity, insulin resistance and T2DM. 
Observational human studies have extensively documented an inverse relationship 
between vitamin D status and obesity-related insulin resistance (60). Vitamin D has been 
shown to stimulate the expression of insulin receptor substrate in muscle tissue of HFD 
mice, (61). Vitamin D directly activates peroxisome proliferator activator receptor-∂ (PPAR-
∂) (62), a transcription factor involved in the regulation of fatty acid metabolism in skeletal 
muscle and adipose tissue. Vitamin D may have an effect on insulin secretion by maintaining 
extracellular calcium, ensuring normal calcium influx through cell membranes and adequate 
calcium pool in the pancreatic beta cells (63). The role of of vitamin D in human lipid and 
glucose metabolism and its deficiency in obesity-associated insulin resistance has been 
reviewed more extensively in chapter 2 of this thesis. 
Vitamin D and adipose tissue metabolism 
 
 As indicated above, the obese insulin resistant state is also often associated 
with low levels of serum vitamin D (Hypovitaminosis D) (64) both in children (65-67) and 
adult men and women (60, 68). Adipose tissue represents a major storage reservoir for 
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vitamin D, which is not surprising giving its characteristics as a fat-soluble vitamin, although 
the underlying mechanisms for the circulating deficiency in human obesity is not clearly 
understood. The enlarged pool of visceral and subcutaneous AT in human obesity probably 
sequestrates vitamin D and its metabolites, reducing their bioavailability (69). Beside 
vitamin D uptake by adipose tissue, there also evidence of release both in mice as well as in 
human adipocytes (70). A recent ex vivo data by Di Nisio et al demonstrated that a blunted 
adrenaline-mediated lipolytic response, a characteristic of the obese insulin-resistant state, 
was accompanied by an increased accumulation of 25(OH)D3 in human SAT from obese 
donors, possibly indicating a blunted vitamin D release (71). However, in vivo data from 
human is rather limited, as more extensively discussed in chapter 2. 
Vitamin D-related genes, obesity, and insulin resistance
 Next to environmental (sun exposure, season) and behavioral (food intake) factors, 
genetic factors may play an important role in determining serum 25(OH)D3 concentrations 
(72). A study in twin male showed that genetic variation in vitamin D related metabolism 
genes may explain more than 50% of the variation in vitamin D metabolite concentrations 
particularly during winter (73). However, genome-wide association studies have shown 
that genetic variants in vitamin D-related genes explain a modest (~10%) of variations in 
circulating vitamin D concentrations (74-77). Genetic variations of vitamin D receptor (VDR) 
is most often associated with vitamin D concentration and metabolic health outcomes (78). 
Vitamin D receptor genetic variants
 Human and animal data indicate that VDR is present at the RNA and protein 
level in adipose tissue (AT) (79) and other insulin sensitive tissues such as liver (80) and 
skeletal muscle (81), thereby contributing to vitamin D-mediated effects on glucose and 
lipid metabolism in these tissues. VDR is known as a member of the superfamily of the 
steroid hormone receptors and is also recognized as a nuclear transcription factor (82). The 
genomic responses to vitamin D result from the interactions between its active metabolite 
[1,25(OH)2D3] and its intracellular VDR. Then, after the binding of vitamin D, VDR forms a 
heterodimer with the retinoid-X receptor (RXR) that binds to specific vitamin D response 
elements (VDREs) on DNA sequences leading to expression or trans-repression of several 
VDR targets genes of which some are involved regulating lipid and glucose metabolism (e.g. 
PPAR-∂, insulin receptor substrate-1) (82, 83).
 The human VDR gene is located on chromosome 12q, which encodes the full-
length VDR protein. FokI, BsmI, ApaI and TaqI (SNPs) have been identified in VDR. Ye et 
al. (84) found that the VDR TaqI T allele was associated with obesity in French Caucasian 
individuals with early onset of type 2 diabetes. A study conducted in a Saudi Arabian cohort 
identified that the VDR TaqI G allele polymorphisms were significantly more frequent in 
obese individuals (84). In a Central-European population, it has been suggested that genetic 
variability in the VDR region (including FokI and ApaI polymorphisms) may be an important 
factor influencing anthropometric characteristics associated with obesity including BMI, Fat 
Mass and body fat distribution (85). Furthermore, a study in Poland showed that the BsmI 
variant may be associated with BMI in men (86), but not in women (87). However, larger 
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genome wide studies in UK (men and women) (88) and Chinese women (89) indicate that 
VDR genetic variants are unlikely a major determinant of obesity related phenotype such 
as BMI, waist circumference (WC), and waist-to-hip ratio (WHR). In addition, it has been 
suggested that FokI variant is related with insulin sensitivity (86). However, is it unknown 
whether these VDR SNPs are associated with insulin sensitivity and to what extent these 
SNPs may affect intervention outcome (vitamin D supplementation), as was explored in 
chapter 2 of this thesis. 
Vitamin D supplementation and insulin sensitivity
 The link between obesity, insulin resistance and vitamin D deficiency may give a 
rational for vitamin D supplementation (90). Therefore, increasing circulating vitamin D levels 
through either vitamin D fortified foods or drinks (91-93) as well as oral supplementation (94) 
has been hypothesized to improve glucose metabolism and insulin sensitivity. Numerous 
randomized controlled trials (RCTs) have been conducted to investigate whether vitamin 
D supplementation has a causal effect on glucose homeostasis and insulin resistance. 
However, the results from these RCTs are still inconsistent and next to only fasting glucose 
measures, as well as indirect markers of insulin sensitivity are used. Some studies suggested 
a beneficial effect to improve insulin sensitivity (94-96), on the other hand, studies did 
not find any beneficial effects on glucose homeostasis and/or insulin sensitivity (97-99). 
Evidence of human interventional studies regarding the effect of vitamin D supplementation 
on glucose homeostasis and insulin sensitivity is described more detail in chapter 2 and 
chapter 6 of this thesis.
Outline of thesis
 This thesis describes the role of vitamin D in human overweight/obesity and whole 
body and tissue-specific insulin sensitivity. As described earlier in this thesis, the link between 
vitamin D deficiency, obesity-related insulin resistance is reviewed in more detail in chapter 
2. In addition, this chapter provides and an extensive overview on the etiology of vitamin D 
deficiency in obesity-related insulin resistance, which covers vitamin D metabolism, the role 
of vitamin D in (tissue-specific) insulin resistance and in increased adiposity (both human 
observational and intervention studies).  Vitamin D is known as a fat-soluble vitamin that 
may accumulate in adipose tissue. 
In human with overweight/obesity, the expanded adipose tissue mass may take up 
and store vitamin D thereby representing as a reservoir (metabolic sink) for vitamin D, reducing 
its bioavailability. To investigate this, in chapter 3 we analyzed the uptake and release of 
vitamin D metabolites [25(OH)D3 and 1,25(OH)2D3] across abdominal subcutaneous adipose 
tissue in lean and obese men following an overnight fast and beta-adrenergic stimulation 
(to stimulate lipid hydrolysis) using state-of-the-art arterio-venous difference methodology. 
In Chapter 4 investigates whether the circulating vitamin D metabolites [25(OH)D3 and 
1,25(OH)2D3] are associated with adipose tissue, muscle and liver insulin sensitivity using the 
gold standard hyperinsulinemic euglycemic clamp in individuals with overweight/obesity. 
Furthermore, vitamin D receptor (VDR) and vitamin D-metabolizing enzymes [cytochrome 
450 (CYP)] expression in adipose tissue (AT) was studied in relation to AT insulin sensitivity.
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 Genetic variants in VDR have been suggested to link with obesity related insulin 
resistance. In Chapter 5 extends the outcome from previous chapter 4 and describes 
the association between genetic variations of VDR, adiposity and (tissue-specific) insulin 
resistance as well as weight loss and weight regain in human with overweight/obesity from 
DIOGENES cohort, a Pan-European, randomized, controlled dietary intervention study 
investigating the effects of dietary protein and glycemic index on weight loss and weight 
maintenance. Several meta-analyses on effect of vitamin D supplementation only focus on 
markers related fasting insulin and glucose concentrations.
In chapter 2, we briefly resumed recent meta-analysis study the effect of vitamin 
D supplementation on glucose metabolism in humans. However, most meta-analyses have 
been executed with fasting measures of glucose and insulin metabolism. In chapter 6 we 
conducted a meta-analysis on the effect of vitamin D supplementation on insulin sensitivity 
derived from Matsuda index, insulin sensitivity index, as well as hyperinsulinemic euglycemic 
clamp methodologies. Finally, in chapter 7 the results of the present thesis are discussed in 
broader perspective.
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Summary
 The obese insulin resistant state is often associated with low circulating 
concentration of vitamin D 25-hydroxyvitamin D3 [25(OH)D3]. Fat sequestration of vitamin D 
in the expanded obese adipose tissue mass has been pointed out as a plausible explanation 
for this circulating vitamin D deficiency. However, the putative mechanisms behind this 
hypovitaminosis D remain to be elucidated. 
 The presence of vitamin D receptor and vitamin D metabolizing enzymes in insulin-
sensitive organs suggests that vitamin D may be involved in glucose and lipid metabolism 
and may be related to insulin sensitivity. Indeed, mainly in vitro studies support a role of 
vitamin D in regulating glucose and lipid metabolism in several insulin sensitive tissues 
including adipose tissue, skeletal muscle, liver, as well as pancreatic insulin secretion. A 
potential role of vitamin D in gut barrier function and metabolism has also been suggested. 
This review summarizes recent knowledge on vitamin D deficiency in the etiology of obesity 
related insulin resistance, and discusses potential underlying mechanisms. Finally, the role 
of vitamin D supplementation on insulin sensitivity and glycemic control will be discussed
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Introduction
 Obesity is a main contributor to the development of type 2 diabetes mellitus 
(T2D) and cardiovascular diseases (CVD) and has become a major public health problem 
worldwide (1, 2). The World Health Organization (WHO) has reported that more than 422 
million people suffer from T2D worldwide.(3) In addition, the prevalence of prediabetes, 
an intermediate condition of fasting and/or postprandial hyperglycemia, has also been 
indicated to sharply increase in several countries (4-6). Much attention has been given to 
the prevention of T2D, with emphasis on the prediabetic state. Compared to normal glucose 
tolerant (NGT) people, 37% of the pre-diabetic individuals develop T2D within 4 years (7), so 
maintaining their blood glucose levels in the normal range may reduce the incidence of T2D 
(8, 9).
 Obesity is generally described as a condition of excessive fat accumulation, with 
abdominal obesity being the leading risk factor for insulin resistance and T2D (10). Obesity–
associated health complications are often accompanied by dysfunctional adipose tissue 
(AT) rather than an increased fat mass per se, which is characterized by impairments in 
lipid storage capacity, particularly in the postprandial state. Hence the surplus energy as 
triglyceride will flow over into the circulation and result in an increased lipid supply towards 
non-adipose tissue organs like the liver and the skeletal muscle (11, 12). Fat deposition 
in these non-adipose tissues may result in functional impairments that contribute to the 
development of whole-body insulin resistance leading to T2D (13). 
 Originally, the fat-soluble vitamin D has been well known as major regulator of 
calcium and phosphate homeostasis related to bone metabolism. There is considerable 
evidence that vitamin D 25-hydroxyvitamin D3 (25OH)D3) deficiency (concentration <50 
nmol/L) is associated with osteoporosis and reduced bone health (14, 15) On the other 
hand, evidence is accumulating that vitamin D has much broader non-skeletal roles in the 
human body than previously thought. In line, vitamin D metabolizing enzymes and vitamin 
D receptors (VDR) are expressed in several insulin-sensitive tissues, suggesting extrarenal 
metabolism and activity of vitamin D (16, 17).  Obesity, insulin resistance and T2D are often 
characterized by a relative circulating vitamin D deficiency (hypovitaminosis D), suggesting 
a role for vitamin D in the pathophysiology of obesity-related metabolic disorders (18-20). 
There is accumulating mechanistic evidence for a role of vitamin D in glucose and lipid 
metabolism in insulin sensitive tissues like the adipose tissue, skeletal muscle and liver (21-
23). In this review, we discuss the latest knowledge on vitamin D metabolism as well as 
its role in glycemic control and lipid metabolism. Firstly, vitamin D metabolism, receptor 
expression and intracellular signaling will be discussed. Additionally, the role of the active 
vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and VDR in controlling tissue 
substrate metabolism and insulin sensitivity will be addressed. Subsequently, data on vitamin 
D status in the obesity-related insulin resistant will be reviewed. Finally, an overview will be 
given from recently published meta-analyses on the effect of vitamin D supplementation to 
improve insulin sensitivity and blood glucose control.
Vitamin D metabolism 
 In human, vitamin D3 can be synthesized from the skin following ultraviolet B (UVB) 
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light exposure (15). Vitamin D2 and D3 from diet also contribute to circulati ng levels of vitamin 
D (24), although their relati ve contributi on to circulati ng vitamin D levels is sti ll unknown. 
Vitamin D3 has a higher affi  nity to bind to vitamin D binding protein (VDBP) and is therefore 
more likely to be hydroxylated in the liver (24). In the liver, the hydroxylase enzyme converts 
vitamin D3 into 25-hydroxyvitamin D3 (25(OH)D3) at the endoplasmic reti culum (25). The 
mechanism by which 25(OH)D3 is released from the liver and subsequently bound to VDBP 
to be transported to the kidneys or extrarenal ti ssues is not well understood (25). 
 25-hydroxyvitamin D3 in complex with its plasma carrier, VDBP, is fi ltered through 
the glomerulus and reabsorbed in the proximal tubules by the endocyti c receptor megalin 
(26). Subsequently, 25(OH)D3 is converted by the 1-α-hydroxylase enzyme to biologically 
acti ve 1,25(OH)2D3 intracellularly.(26, 27) Dysfuncti on of these receptors, which is commonly 
found in pati ents with diabeti c nephropathy, even at early stages, may explain why vitamin 
D defi ciency is oft en observed in these pati ents (27).
 Interesti ngly, recent in vitro studies have shown that megalin is involved in the 
uptake and release of vitamin D 25(OH)D3 in murine muscle cells (28), whereas cubilin is 
involved in uptake and release of vitamin D 25(OH)D3 in mice white adipocytes (29). The 
presence of functional VDR and vitamin D metabolizing enzymes was identifi ed at the 
transcriptional and protein level in murine muscle (30) and adipose tissue (31) indicating 
extrarenal vitamin D metabolism. Uptake and release of 25(OH)D3, in mice adipose and 
muscle cells has been investigated (29, 32), which was regulated by VDR and its ligand 
(1,25(OH)2D3) in a time dependent-manner (33). Thus, vitamin D uptake and release in tissues 
like muscle and adipose tissue might be tightly regulated (29, 34).  
Figure 1. Metabolic eff ects of Vitamin D on insulin sensiti ve ti ssues including adipose ti ssue metabolism, muscle 
glucose/lipid metabolism, liver metabolism, pancreati c insulin secreti on, and gut-intesti nal functi on. Of note, 
majority of evidence for these functi onal eff ects are derived from in vitro and animal models which warrant further 
investi gati ons in human. (↑) increase; (↓) decrease; references between brackets [].
 
 The vitamin D receptor belongs to the nuclear receptor family, thereby controlling 
DNA transcripti on.(35) Briefl y, the cytosolic VDR-1,25(OH)2D3 complex translocates to the 
nucleus where it subsequently interacts with reti noic acid X receptor (RXR) to form RXR-
VDR complexes that bind to specifi c DNA regions called vitamin D response element (VDRE) 
regions, hence regulati ng VDR-targeted gene expression (36). Although the VDR primarily 
acts as nuclear transcripti on factor, it is postulated that non-genomic acti ons of vitamin D 
involve rapid binding of 1,25(OH)2D3 to both cytosolic and membrane VDR which acti vates 
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several second messenger systems (37, 38). Interestingly, a VDRE was identified in the 
promoter of the human insulin receptor gene, indicating vitamin D might be involved in the 
transcriptional control of insulin signaling (39). 
Role of vitamin D in adipose tissue lipid metabolism 
 VDR mRNA expression was identified in visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT) of lean and obese. In VAT, expression of VDR was higher 
in obese than in lean, where as no difference of VDR expression in SAT was observed (40). 
In addition, VDR protein expression has recently been demonstrated in primary adipocytes 
derived from obese donors (21), indicating the possible involvement of vitamin D in AT 
development and metabolism. Indeed, recent studies suggest a role of vitamin D in AT 
adipogenesis, lipogenesis, lipolysis, and inflammation (21, 41-43). 
Adipogenesis
 An in vitro study using 3T3-L1 preadipocytes has shown that treatment with 
1,25(OH)2D3 (10nM) suppresses the major adipogenic transcription CCAAT enhancer binding 
protein alpha/beta (CEBPα/β) and peroxisome proliferator activated receptor-γ (PPAR-γ) in a 
VDR dependent manner, resulting in inhibition of adipogenic differentiation (44). Of interest 
1,25(OH)2D3 was added to the medium in the early phase of differentiation. In contrast when 
10 nM 1,25(OH)2D3 was added in the late phase of differentiation, there was an increased 
mRNA expression of adipogenic markers like PPAR-γ, CEBPα/β, Fatty Acid Binding Protein 
4 (FABP4), and Fatty Acid Synthase (FASN) in  AT from human multipotent adipose-derived 
stem cells (hMADS) and subcutaneous pre-adipocytes (21, 41). A recent study has suggested 
1,25(OH)2D3 (10 nM) upregulated CEBP expression after 24h of induction of differentiation 
in  human SGBS cells (45). It is likely that treating cell with vitamin D at different stages of 
differentiation could partly explain these opposite findings in human primary adipocytes 
(21, 41) as compared to murine cell model (44). Nevertheless, taken together, these data 
suggested that vitamin D might affect adipogenesis (Figure 1) at the transcriptional level, at 
least in a species specific manner. 
Lipogenesis
 
 Incubation of differentiated subcutaneous human adipocytes derived from male 
and female donors with a wide range of BMI (25.6–50.9 kg/m2) with 10 nM 1,25(OH)2D3 (for 
24 hours) increased the protein expression of the lipogenic enzyme fatty acid binding protein 
4 (FABP4), the mRNA expression of lipoprotein lipase (LPL), and increased  triacylglycerol 
(TAG) accumulation as compared to control adipocytes (41). Furthermore, incubating 
human adipocytes with 5 nM 1,25(OH)2D3 increased FAS protein level (46). Upregulation 
of FAS by 1,25(OH)2D3 is likely mediated by the VDR(21) and VDR activity may be necessary 
for lipid accumulation in the late phase of adipogenesis (47). However, in vivo injection of 
1,25(OH)2D3 (1g/kg/day) in Sprague-Dawley rats (16 days) did not increase mRNA expression 
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of FAS in AT (48). These findings indicate that vitamin D may modulate lipogenic enzymes 
expression at least in vitro (Figure 1), therefore human in vivo studies are required to clarify 
these findings in vitro.
 
Lipolysis
 A study by Xue et al. showed that 1,25(OH)2D3 (5 nM) inhibits basal and beta-
adrenergically mediated lipolysis in human adipocytes, possibly via increased intracellular 
calcium levels resulting in decreased cAMP levels and a reduced hormone-sensitive lipase 
(HSL) phosphorylation (46, 49). In contrast, recent data by Chang et al. (42) and Larrick 
et al(50) showed that 1,25(OH)2D3 increased glycerol release both under basal and beta-
adrenergically stimulated conditions in murine 3T3-L1 adipocytes (42). This increased 
lipolysis was accompanied by increased mRNA expression of the lipase HSL, and markers 
of fat oxidation, and mitochondrial biogenesis/function like carnitine palmitoyltransferase 
1 (CPT1α), PPARα, co-activator proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1α) and sirtuin 1 (SIRT1) (42). Thus, data on the effect of vitamin D and lipolysis in 
human primary and murine adipocytes are still inconsistent (Figure 1).
Inflammation: cytokine-adipokine production
 Low-grade circulating inflammation and increased AT infiltration of immune cells 
are strongly associated with local adipose tissue and whole-body insulin resistance. In vitro 
studies using murine 3T3-L1 adipocytes and human pre-adipocytes have shown that pro-
inflammatory markers (e.g. IL-6, MCP-1, IL-1β) and TNF-α-derived macrophage activity is 
reduced following treatment with 10 nM of 1,25(OH)2D3, and this effect is partly mediated by 
VDR (51, 52) In line, recent in vivo findings in Sprague-Dawley male mice following 12-weeks 
combined High Fat and Low Vitamin D Diet (HFD+LVD) have demonstrated an increase in 
AT macrophage infiltration, IL-6 and TNF-α mRNA and protein expression compared to 
the HFD+1000 IU Vitamin D/Kg group (53). NFκB/MAPK mediated mechanisms have been 
described to explain the possible anti-inflammatory action of the VDR-ligands in murine 
adipocytes,(54, 55) as well as human preadipocytes (56). 
In summary, the current available in vitro and animal data indicate that vitamin D 
may affect AT lipid buffering capacity by affecting adipogenic differentiation, lipogenesis, 
intracellular lipolysis, and oxidative capacity (the latter via effects on mitochondrial 
biogenesis/function). Furthermore, Vitamin D may have beneficial effects on local AT and 
systemic low-grade inflammation via activation of NFκB/MAPK mediated pathways (Figure 
1).  Currently, there is a gap between data available from in vitro studies using animal-human 
derived cell models and well-controlled human intervention studies. 
Role of Vitamin D on muscle glucose and lipid metabolism
 As indicated above, vitamin D deficiency may affect AT lipid buffering capacity, 
thereby altering fatty acid supply to skeletal muscle and indirectly affecting muscle lipid 
content (preventing lipotoxicity). Additionally, direct effects of vitamin D on skeletal muscle 
544591-L-bw-Pramono
Processed on: 28-7-2020 PDF page: 29
CHAPTER 2
Vitamin D deficiency in the aetiology of obesity-related insulin resistance
29
metabolism have also been described. For instance, L6 and C2C12 myotubes treated with 
100 nM (24h) and 10nM of 1,25(OH)2D3 (72h) showed an elevated  glucose transporter 4 
(GLUT4), VDR and Insulin Receptor (IR) mRNA expression, but functional effects on glucose 
uptake were not determined (57, 58). In line, C2C12 mouse myotubes treated with 10nM 
1,25(OH)2D3 for 48h ameliorated lipid-induced insulin resistance, through improved insulin 
receptor substrate-1 (IRS-1) tyrosine phosphorylation and increased serine phosphorylation 
of protein kinase B (PKB), also known as Akt (59, 60). Additionally, 1,25(OH)2D3 increased 
mRNA content of Perilipin 2 (PLIN 2,) as well as  adipose triglyceride lipase (ATGL) in C2C12 
myotubes (22), indicating an involvement of vitamin D in muscle lipolysis and intramuscular 
lipid catabolism. 
 Furthermore, treatment of human primary muscle cells from healthy lean donors 
with 10 nM 1,25(OH)2D3 resulted in an improved mitochondrial morphology (volume and 
structure) and altered mRNA expression of genes involved in muscle glucose and lipid 
metabolism like pyruvate dehydrogenase kinase 4 (PDK4) and CPT1 (61), These in vitro 
animal and human data indicate that vitamin D may affect muscle insulin sensitivity via 
improvement of mitochondrial function, substrate oxidation, and lipid turnover (Figure 
1). However, future investigations are needed to elucidate the physiological importance of 
vitamin D in muscle substrate handling and insulin sensitivity in humans.
Role of Vitamin D in liver lipid and glucose metabolism
 Obesity is often associated with excessive fat deposition in the liver causing 
inflammation and hepatic insulin resistance (62). An imbalance between lipid availability 
(from adipose tissue lipolysis or de novo lipogenesis) and lipid removal (via fatty acid oxidation 
or triglyceride-rich lipoprotein secretion) in the liver can result in hepatic lipid accumulation, 
leading to non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) 
(63). 
 In vivo and in vitro studies in rodents have provided insight into the putative 
mechanisms through which vitamin D may lower liver lipid accumulation possibly via effects 
on the enterohepatic circulation and autophagy. Intrahepatic injection of 1,25(OH)2D3 
(5 ng/g body weight, twice per week) for 4 weeks in HFD+VDD treated mice resulted in 
an upregulation of bile acids transport, suppressed gene expression related to hepatic 
lipogenesis and proinflammatory markers, thereby  improving the NASH phenotype.(23) 
In line, intraperitoneal injection of 1,25(OH)2D3 (2.5 ng/g body weight 3 times per week) 
for 4 weeks significantly reduced liver lipid accumulation in mice (64). As shown in HepG2 
cells, 1,25(OH)2D3 may ameliorate hepatic steatosis by upregulating autophagy-related 
(i.e. ATG16L1) mRNA expression, indicating that vitamin D might induce lipophagy via the 
autophagy-lysosomal pathway (64).
 Nelson and colleagues showed that serum 25(OH)D3 levels are inversely associated 
with hepatocyte damage, as reflected by hepatocellular ballooning degeneration, in obese 
men and women with NASH (65). However, another study has reported no correlation 
between serum vitamin D and liver fat accumulation nor liver insulin sensitivity and 
inflammation in obese men and women with NASH (66). These data indicate that studies 
on the association between vitamin D, liver fat and liver insulin sensitivity and inflammation 
in humans are inconsistent, despite accumulating mechanistic evidence from in vitro and in 
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vivo rodent models (Figure 1).
Role of Vitamin D in insulin secretion 
 Obesity-associated insulin resistance may chronically elevate glucose and fatty acids 
in the circulation accompanied by a decline in beta cell function, resulting eventually in a 
reduced insulin secretion. Therefore, improving beta cell insulin secretion or responsiveness 
has a major effect on glycemic control (67, 68). 
 Incubation of beta cells derived from VDD mice with 1 nM 1,25(OH)2D3, pretreated 
with high-glucose, resulted in a reduced mRNA and protein expression of Renin Angiotensin 
System (RAS) components (69), of which involvement in insulin secretion has been 
demonstrated in a T2D mice model (70). In addition, incubation of pancreatic cell islets from 
type 1 diabetic donors with 1,25(OH)2D3 increased VDR expression and prevented cytokine-
induced FAS expression (mRNA and protein), which is a mediator of beta-cells apoptosis 
(71). A recent in vitro study has suggested that a VDR-ligand (Calcipotriol/derivative of 
1,25(OH)2D3) may protect human ß-like cells (derived from human induced pluripotent stem 
cells/iPS) against interleukin 1ß-mediated inflammation (72). Together, these data suggest 
that vitamin D may affect pancreatic insulin secretion in a RAS dependent manner, via 
induction of beta-cell apoptosis, and may protect beta-cell from local inflammation (Figure 
1). Furthermore, the putative underlying mechanisms for the effect of vitamin D on insulin 
secretion and glycemic control in human pancreatic islets remain to be determined. 
Role of Vitamin D in gut 
 It is well-known that intestinal calcium balance can be modulated by vitamin D 
through stimulating intestinal calcium absorption as shown in human and animal studies 
(73, 74). The presence of the VDR and the expression of CYP27B1 in small and large 
intestinal epithelial and immune cells indicate the biological and metabolic significance 
of vitamin D in the human gut (75). Interestingly, it has been shown that vitamin D3 
supplementation for 4 weeks results in an increased microbial diversity and a decrease in 
relative abundance of Gammaproteobacteria in the upper gastro-intestinal tract in healthy 
men and women (76). Furthermore, intraperitoneal injection of 1,25(OH)2D3 (5 ng/g body 
weight) for one month attenuated metabolic endotoxemia (as evidenced by lower plasma 
lipopolysaccharides, LPS), and improved intestinal tight junction integrity, as well as Paneth 
cell defense in HFD+VDD fed mice (77). An elegant review by Zheng and colleagues showed 
that evidence is accumulating for a role of Vitamin D in improved beta cell function in Type 
1 Diabetes (T1D), possibly via effects on the microbiome (78). Nevertheless, the underlying 
mechanisms still need further investigations. Overall, these findings indicate that vitamin D 
may have important roles in intestinal barrier function, local inflammation and modulation 
of microbial composition (Figure 1). 
Vitamin D status in the obese insulin resistant state
 Inverse correlations between serum 25(OH)D3 and weight, BMI, and waist 
circumference have been shown in overweight and obese adults with different ethnic 
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backgrounds (79). Low circulati ng 25(OH)D3 concentrati ons in human obesity might be due 
to increased uptake and sequestrati on of fat-soluble vitamin D in the increased fat mass, 
though the underlying mechanism is unclear (80). In line, diluti on of vitamin D due to a 
higher volume distributi on in obese has been proposed as underlying mechanism for the 
inverse correlati on between body size (body weight) and serum 25(OH)D3 concentrati ons 
(81). In additi on, obese individuals may spend less ti me outdoors, which may result in 
reduced endogenous vitamin D producti on contributi ng to the lower circulati ng vitamin D 
levels observed in obesity (82). Interesti ngly, Wamberg and colleagues showed that VDR 
expression was comparable between VAT and SAT from obese individuals, but higher in 
VAT from obese individuals compared with VAT from lean individuals (40). The expression 
of 25-hydroxylase enzymes (CYP2J2, CYP27A1 and CYP27B1) was decreased in SAT from 
obese individuals (40). These data indicate an impaired adipose ti ssue vitamin D related 
metabolism  of obese individuals (Figure 2). However, it is sti ll unclear whether this 
impaired adipose ti ssue vitamin D related metabolism is aff ected by circulati ng vitamin D 
concentrati ons, insulin resistance or adiposity per se in human obesity.
Figure 2. Obesity is oft en accompanied with low circulati ng vitamin D levels (vitamin D defi ciency). External factors 
such as less sun exposure and less outdoor physical acti vity may be associated with low circulati ng vitamin D levels 
in human obesity. Furthermore, endogenous mechanisms, including increased body fl uid distributi on and adipose 
ti ssue dysfuncti on, might also contribute to increased vitamin D sequestrati on and an impaired vitamin D release 
in human obesity, which may ulti mately lead to the development of insulin resistance. (↑) increase; (↓) decrease; 
references between brackets [].  
 
 Fat mass reducti on has been considered as a strategy to increase circulati ng 
vitamin D in obesity. For instance, energy restricti on using a very low-calorie diet (VLCD, 
500 kcal per day) combined with physical acti vity increased plasma 25(OH)D3 levels aft er 
1 year interventi on in obese individuals, which was inversely related with the reducti on 
of VAT volume (83). In contrast, the intensive lifestyle Diabetes Prevention Program (DPP) 
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showed that a decrease total body fat was not associated with increased plasma 25(OH)D3 
concentration in prediabetic individuals (84). In addition to lifestyle intervention, weight-
reducing surgery using gastric bypass only resulted in a temporal elevation of serum 25(OH)
D3 levels, which decreased again one month after surgery (85). Furthermore, two systematic 
reviews and one meta-analysis concluded that weight loss interventions showed only 
marginal changes in serum 25(OH)D3 following significant weight and body fat loss (86, 87). 
Thus, the above studies provide inconsistent evidence on the relation between AT mass 
and the circulating levels of serum 25(OH)D3. Therefore, it may be that the often observed 
circulating vitamin D deficiency in obesity is more complex than previously thought and 
cannot be solely explained by increased sequestration/dilution in the expanded AT mass.
 Of interest, recent ex vivo data by Di Nisio et al (88) demonstrated that a blunted 
adrenaline mediated lipolytic response, a characteristic of the obese insulin resistant state 
was accompanied by increased accumulation of 25(OH)D3 in human subcutaneous adipocytes 
from obese donors, possibly indicating a blunted vitamin D release.  Thus, there may be an 
important link between an impaired lipid mobilization/turnover and an attenuated vitamin 
D release from the AT in obese-insulin resistant individuals which remains to be investigated 
in more detail.
Vitamin D, blood glucose control and insulin sensitivity
 The potential effects of vitamin D on glucose homeostasis and insulin sensitivity have 
been studied in numerous human cross-sectional and intervention studies. The majority of 
these cross-sectional studies showed a positive association of serum 25(OH)D3 levels with insulin 
sensitivity measures derived from a hyperinsulinemic euglycemic clamp test(89, 90) or indirect 
markers such as Matsuda index (91), or Quantitative Insulin Sensitivity Index (QUICKI)(92, 93). 
A negative association was observed with Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR)(93) or 2-hour Oral Glucose Tolerance Test (2h OGTT) (94), However, in most studies the 
relationship between serum 25(OH)D3 and markers of insulin sensitivity/resistance attenuated 
(95, 96) or even disappeared (94, 97) after adjustment for  markers of adiposity (including BMI, 
and/or body fat percentage). This indicates that the association between vitamin D deficiency 
and degree of insulin resistance in obese individuals, may be mediated mainly by the increased 
body weight and changes in body composition.
Evidence from human intervention studies
 Obesity-associated with circulating vitamin D deficiency may cause a decreased vitamin 
D bioavailability. Therefore, increasing circulating vitamin D levels by means of supplementation, 
is expected to affect tissue function and insulin sensitivity in the obese resistant state. As 
shown in table 1, eight meta-analyses published between 2012 and 2018 (98-105) of human 
intervention carried out between 1980 and 2017 showed an increased plasma vitamin D 25OHD3 
concentration following supplementation, but the majority of these meta-analyses suggested 
insufficient evidence to no effects on glycemic control and insulin sensitivity/resistance. The 
included interventions were performed across different ethnicities, in both sexes, and with a 
broad spectrum of vitamin D doses, modes of administration, treatment duration and most often 
used surrogate markers of insulin resistance.
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Table 1. Meta-analyses of RCTs regarding the effect of vitamin D supplementation on insulin 
sensitivity and glucose metabolism
Abbreviations: 2OGTT: 2-hour Oral Glucose Tolerance Test; FPG: Fasting Plasma Glucose; HOMA-IR: Homeostatic 
Model Assessment of Insulin Resistance; HbA1C: Glycated Haemoglobin; IGT: Impaired Glucose Tolerance; MD: 
Mean Difference; NGT: Normal Glucose Tolerance; SMD: standardized mean difference; WMD: weighted mean 
difference; T2D: Type 2 Diabetes. 
 Focusing on humans with obesity, a meta-analysis in 1181 subjects with overweight/
obesity (100), including sub-analysis based on dosage (high vs. low), duration (long term vs. 
short term), and group (vitamin D deficient vs. non-deficient) showed no effect of vitamin 
D supplementation on glucose metabolism and insulin resistance. Furthermore, subgroup 
analysis suggested that insulin resistance is improved in non-obese as compared to obese 
subjects (102-104). Together, these data may point towards no direct causality between 
circulating vitamin D concentration and development of insulin resistance in humans with 
obesity.
Conclusion and future recommendations
 This review reports that obesity and insulin resistance are often associated 
with circulating vitamin D deficiency, which may be partly explained by an increased 
sequestration/dilution in the expanded AT mass. Additionally, vitamin D metabolism within 
the AT may also be altered as reflected by a down-regulation of vitamin D metabolizing 
enzymes and the finding of an impaired (lipolysis-mediated) release of vitamin D 25(OH)D3. 
However, further studies are needed to determine the underlying mechanism in humans 
with obesity. 
 The role of vitamin D in tissue specific glucose and lipid metabolism is still under 
debate in humans. Data from mostly murine and in vitro studies indicate that vitamin D 
possibly contributes to the improvement of AT lipid buffering or fat storage capacity and may 
reduce the pro-inflammatory state, but data are not entirely consistent and human evidence 
is lacking. Vitamin D has also been implicated in muscle insulin signaling, intramuscular 
lipid partitioning as well as liver inflammation and steatosis. However, these (murine) in 
vitro findings have not been followed by consistent human in vivo evidence on whole-body 
Investigators (Year) N trials included Study Populations Markers of glucose & insulin (effect size) Outcome
-  FPG (SMD –0.02; 95% CI: –0.10 to 0.06; P=0.59) 
-  HOMA-IR (SMD –0.07; 95% CI: –0.20 to 0.06; P = 0.30)
-  HbA1c (SMD 0.03; 95% CI: –0.18 to 0.23; P=0.81)
-  FPG (SMD -0.10; 95% CI: –0.26 to 0.07; P=0.25)
-  HOMA-IR (SMD 0.04; 95% CI: –0.44 to 0.52; P=0.86)
-  FPG (WMD -3.59; 95%CI: -7.94 to 0.76; P=0.11)
-  HOMA-IR (SMD –0.57; 95%CI: −1.09 to −0.04; P=0.03)
-  HbA1c (WMD -0.11; 95%CI: -0.35 to 0.13; P=0.38)
-  FPG (SMD -0.27; 95%CI: -8.1 to -1.6; P=0.003)
-  HOMA-IR (SMD: -0.66; 95%CI: -1.06 to -0.26; P = 0.001)
-  HbA1c (SMD: -0.30; 95%CI: -0.45 to -0.15; P<0.001)
-  FPG (WMD –0.46; 95% CI: –0.74 to –0.19; P=0.001)
-  HOMA-IR (WMD –0.39; 95% CI: –0.68 to –0.11; P=0.007)
-  HbA1c (WMD –0.48; 95% CI: –0.79 to –0.18; P=0.002)
-  FPG (MD –0.10; 95% CI: –0.18 to –0.03; P = 0.006)
-  HbA1C (MD –0.89; 95% CI: –1.54 to –0.23; P = 0.008)
-  HOMA-IR (MD –0.06; 95% CI: –0.36 to 0.24; P = 0.69)
-  2hOGTT (MD –0.23; 95% CI: –0.65 to 0.19; P=0.28)
-  HOMA-IR (MD –0.04; 95% CI: –0.03 to 0.22; P = 0.77)
-  HbA1c (MD –0.05; 95% CI: –0.12 to 0.03; P=0.20)
-  FPG (SMD −0.14; 95%CI: −0.31 to 0.03; P=0.10)
-  HbA1c (SMD −0.25; 95%CI: −0.45 to −0.05; P=0.001) 
George et al. (2012) 15 RCTs from 1984 to 2010 
Subjects with NGT and 
IFG
No effect 
Jamka et al. (2015)
12 RCTs between 2007 and 
2014 
Subjects with Obesity No effect
Li et al. (2018)
20 RCTs between 2008 and 
2017
Subjects with T2D
Insufficient 
evidence
Mirhosseini et al.(2017)
24 RCTs between 2009 and 
2016 
Subjects with T2D
Sufficient 
evidence 
Mirhosseini et al.(2018)
28 RCTs between 2009 and 
2017 
Prediabetes
Sufficient 
evidence 
Poolsup et al. (2016) 
10 RCTs between 2007 and 
2014 
Subjects with Prediabetes 
(based on IFG or IGT) 
Insufficient 
evidence
Seida et al. (2014)
36 RCTs between 1984 and 
2013 
Subjects with NGT, 
Prediabetes, T2D
No effect 
Wu et al.  (2017)
24 RCTs between 2007 and 
2016
Subjects with T2D
Insufficient 
evidence 
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and peripheral (muscle, liver and adipose) insulin sensitivity. Overall, the current published 
meta-analyses do not support the use of vitamin D supplementation for improving glycemic 
control and insulin sensitivity in overweight/obese humans. Nevertheless, it should also be 
noted that a universal approach (one size fits all) for vitamin D deficiency related-insulin 
resistance may not be appropriate. Perhaps ethnic/geographical location and genetic 
variations of vitamin D-related metabolism (106, 107)  may influence responses to, and 
benefits of, vitamin D supplementation (104, 108). Therefore, further evaluation of genetic 
determinants of vitamin D status among different ethnic/geographical groups and metabolic 
phenotype may enable the identification of population subgroups, which may benefit from 
vitamin D supplementation. Finally, combining vitamin D supplementation with other modes 
of intervention (e.g. diet, exercise, polyphenols, or other micronutrients) might provide new 
strategies for the treatment and prevention of insulin resistance in humans but this needs to 
be investigated under well-controlled human settings.
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Abstract 
 Obesity is characterized by a blunted lipolytic response in abdominal subcutaneous 
adipose tissue (SAT) and low circulating vitamin D levels. Here, we investigated whether an 
impaired SAT lipolytic response coincides with an impaired SAT vitamin D release in eight 
lean and six obese men. 25-hydroxyvitamin D3 [25(OH)D3] and 1,25-dihydroxyvitamin D3 
[1,25(OH)2D3] fluxes across SAT were measured using arterio-venous blood sampling in 
combination with AT blood flow measurements after an overnight fast and during 1-hour 
intravenous infusion of the non-selective ß-adrenergic agonist isoprenaline (20 ng.kg FFM-1.
min-1). 1,25(OH)2D3 was released across abdominal SAT during isoprenaline infusion in lean 
[-0.01 (-0.04 to 0.00) pmol*100g tissue-1*min-1, P=0.017 vs. zero flux], but not in obese men 
[0.01 (0.00 to 0.02) pmol*100g tissue-1*min-1, P=0.116 vs. zero flux], and accompanied by 
an impaired isoprenaline-induced lipolytic response in abdominal SAT of obese versus lean 
men. Isoprenaline had no significant effects on net 25(OH)D3 release across abdominal 
SAT and plasma vitamin D metabolites in lean and obese men. To conclude, a blunted 
isoprenaline-mediated lipolysis is accompanied by reduced release of 1,25(OH)2D3 vitamin D 
across abdominal SAT in obesity.
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Introduction
 Obesity is associated with adipose tissue (AT) dysfunction, which is characterized 
by adipocyte hypertrophy, AT inflammation and impaired lipid metabolism, thereby 
contributing to insulin resistance (1). Noteworthy, obesity is often characterized by low 
circulating vitamin D levels (2). In line, studies have described an inverse association 
between body mass index (BMI) and circulating concentration of the inactive vitamin D 
metabolite 25-hydroxyvitamin D3 (25(OH)D3) (3). Obesity-associated insulin resistance is 
often accompanied by dysfunctional adipose tissue (AT), which might also contribute to 
increased vitamin D sequestration and an impaired vitamin D release in human obesity (4).
 Uptake and sequestration of vitamin D in the expanded obese AT mass may partly 
contribute to the relatively low vitamin D concentrations in the circulation in obesity (5), 
although the underlying mechanism is not yet clearly understood. Furthermore, evidence in 
rodents suggests that vitamin D may also be released from adipose tissue into the circulation 
(6). Obesity is characterized by increased lipid storage in the form of triacylglycerol (TAG), 
mainly in adipose tissue. Catecholamine stimulation leads to an increase in adipose 
tissue lipolysis, thereby resulting in the hydrolysis of TAG stored in lipid droplets (1). Since 
vitamin D is a lipophilic vitamin that has been postulated to accumulate in adipose tissue, 
deliberation of TAG may coincide with release/mobilization of vitamin D metabolites from 
adipose tissue (7). In line with our hypothesis, Di Nisio et al have shown that adipose 
tissue derived from obese individuals releases less vitamin D ex vivo when stimulated with 
adrenaline compared to lean subjects. In the latter study, impaired mobilization of vitamin 
D coincided with blunted catecholamine-induced lipolytic response, determined by glycerol 
release into the medium. Nevertheless, other mechanisms like competition between some 
free fatty acids and vitamin D for binding sites to vitamin D binding protein (DBP) (8) or a 
role of adipose tissue blood flow (ATBF) in relation to both lipolysis and vitamin D release 
may possibly be involved. Therefore, it is tempting to speculate that low circulating vitamin 
D levels in human obesity might be due to an increased uptake and/or a blunted release 
of vitamin D across abdominal subcutaneous AT (SAT), which may occur concurrently with 
the often observed blunted catecholamine-mediated lipolysis (9). However, it remains to 
be determined whether ß-adrenergic stimulation induces vitamin D 25(OH)D3 [inactive 
metabolite] as well as 1,25(OH)2D3 [active metabolite] release across human SAT in vivo. 
In the present study, using arterio-venous methodology, we investigated (1) the 
effect of ß-adrenergic stimulation on net release of vitamin D 25(OH)D3 [inactive] and 
1.25(OH)2D3 [active metabolite] across abdominal SAT in lean and obese men, and (2) 
whether an impaired release of vitamin D across obese abdominal SAT is accompanied by a 
blunted lipolytic response in obese men. 
Methods
Study participants
 The participants of this study were a subset of previous study (Jocken et al, 2008). 
Eight lean (BMI <25 kg/m2) and six obese (BMI >30 kg kg/m2) men were included in this 
analysis. Inclusion criteria for both groups were that participants had to be weight-stable 
(weight change <3.0 kg) for at least 3 months prior to the study, were in good health as 
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assessed by medical history, were free of any medication and spent not more than 3h of 
organized sports activities a week. Exclusion criteria were smoking, cardiovascular disease, 
type 2 diabetes mellitus, liver or kidney malfunction, use of medication known to affect body 
weight and glucose metabolism, or untreated hypertension. The Medical Ethical Committee 
of Maastricht University (MEC-03-179) approved the study which was performed according 
to the procedures set by the latest version of the Declaration of Helsinki, and written 
informed consent was obtained from all participants.
Study Design
 In this study, participants were allowed to perform only light-intensity physical 
activity (for examples: walking slowly (in the office), sitting in front of computer/TV, and no 
sports activities) 2-3 prior to the test day. All participants were asked to refrain from drinking 
alcohol and to perform no strenuous exercise for 24 h before the study. Participants came 
to the university and underwent arterio-venous (A-V) blood sampling across abdominal 
SAT after an overnight fast and after 1 hour intravenous infusion of the nonselective 
ß-adrenergic agonist isoprenaline (20 ng (kg FFM)−1 min−1), as previously described (9). 
Circulating concentrations and fluxes across abdominal SAT of glycerol and vitamin D were 
measured following a 3 hour primed (3µmol.kg-1) constant infusion of [2H5]glycerol (0.2 
umol.kg-1.min-1). Blood samples were taken simultaneously from the arterialised venous 
blood was sampled from a superficial dorsal hand vein and adipose vein at three baseline 
time points (t90, t105 and t120 min) and at three time points during the last 30 min of 
isoprenaline infusion (t150, t165 and t180 min). Adipose tissue blood flow (ATBF) was 
monitored continuously using the 133Xe wash-out technique. Lean and obese subjects were 
studied throughout the year in random order, thus the comparison between groups was not 
confounded by seasonal variation. 
Laboratory analysis 
 Blood samples were transferred into ice-chilled polypropylene tubes and were 
centrifuged (1000 g, 4 °C, 10 min). Plasma was immediately frozen in liquid nitrogen and 
safely stored at -80 °C until analyses. It has been previously demonstrated that when 
immediately frozen (at -80oC), vitamin D metabolites are stable for many years (10-14). 
Vitamin D 25(OH)D3 and 1,25(OH)2D3 levels were measured in arterialized and venous 
plasma samples. Plasma samples at time-points t90, t105 and t120 min (steady state for 
lipolysis at baseline) and t150, t165 and t180 min (steady state for lipolysis during ISO) were 
pooled because of a lack of sample material at the same time point for all subjects. There 
was a steady state at baseline as well as during ISO so that pooling was justified. Vitamin D 
metabolites were analyzed using liquid-chromatography tandem-mass spectrophotometry 
(LC-MS/MS) (15). Stable isotope enrichment of glycerol was measured using GC-MS as 
described previously (9).
Calculations
 Net vitamin D 25(OH)D3 and 1,25(OH)2D3 fluxes across SAT were calculated by 
multiplying arterial-venous (A-V) concentration differences by adipose tissue plasma flow, 
544591-L-bw-Pramono
Processed on: 28-7-2020 PDF page: 45
CHAPTER 3
Vitamin D release across abdominal adipose tissue in lean and obese men: the effect of ß-adrenergic stimulation
45
as described in other contexts (9, 16). Tissue blood flow during baseline is an average of 
time-points t90, t105, t120 min and during ISO is an averaged of t150, t165 and t180 min. 
Plasma flow was calculated as tissue blood flow multiplied by (1 – haematocrit/100), with 
haematocrit expressed as a fraction. Positive fluxes indicate net uptake from the circulation, 
whereas negative fluxes indicate net tissue release into the circulation. The SAT total 
glycerol uptake was calculated as described previously according to the steady state Steele’s 
equation. Abdominal SAT total glycerol release was calculated by subtracting abdominal SAT 
net glycerol flux to abdominal SAT total glycerol uptake (9).
Statistical Analysis
 Subjects characteristics were normally distributed, data are presented as mean 
± standard deviation (SD), and differences between lean and obese were tested using 
Student’s unpaired t test. Since vitamin D metabolites, net fluxes, and adipose tissue blood 
flow were not normally distributed, a non-parametric Mann-Whitney test was used for 
group comparisons. The effects of ß-adrenergic stimulation within groups were tested using 
the Wilcoxon signed-rank test, and data presented as median (range). Kruskal Wallis test 
was performed in order to analyze the difference between groups. A Spearman correlation 
was performed to analyse the relationships between vitamin D fluxes, glycerol, NEFA and 
circulating vitamin D levels. Statistical calculations were performed with SPSS for Macintosh 
(version 21.0; SPSS, Chicago, IL, USA).
RESULTS
Subject characteristics
 Table 1 shows that lean and obese subjects had a comparable age. By definition, 
BMI, body fat percentage, body fat mass as well as homeostasis model assessment for insulin 
resistance (HOMA-IR) were significantly higher in obese compared with lean participants (all 
P<0.01).
Adipose tissue blood flow (ATBF)
Table 1. Characteristics of participants
Characteristics Lean (N=8) Obese (N=6)
Age (years) 50 ± 9 53 ± 9
BMI(kg/m
2
) 23.7 ± 1.3 32.3 ± 2.2**
Waist (cm) 88.9 ± 3.1 110.2 ± 7.3**
WHR 0.9 ± 0.03 1.0 ± 0.03*
BF(%) 21.5 ± 3.0 31.8 ± 1.6**
FM (kg) 16.2 ± 2.0 31.4 ± 4.5**
HOMA-IR 1.8 ± 0.7 3.6 ± 1.0*
*P<0.01; **P<0.001, values are mean ± SD
BF, body fat; BMI, body mass index; FM, fat mass; HOMA-IR, homeostatic model assessment for insulin resistance; 
WHR, Waist to Hip Ratio..
 
 Adipose tissue blood flow (ATBF) was comparable between lean and obese 
individuals at baseline (P=0.108). As expected, Isoprenaline significantly increased ATBF both 
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in lean [1.8(1.3–2.9) vs. 4.8(2.6–11.1 ) ml (100 g ti ssue)-1min-1; P=0.01) and obese [1.3(1.2–
2.4) vs. 3.2(2.1–6.2) ml (100 g ti ssue)-1min-1; P=0.03] men. Importantly, this increase was not 
diff erent between groups (P=0.245).
Systemic (arterialized) concentrati ons and net vitamin D release across abdominal SAT
Vitamin D 25(OH)D3
Plasma arterialized 25(OH)D3 did not diff er between lean and obese individuals at 
baseline (56.1(16.0–84.5) vs 49.6(33.5–63.4) nmol/L, respecti vely, P=0.852). Additi onally, 
no net  25(OH)D3 release across abdominal SAT was observed at baseline in both lean 
[0.02(-5.2–5.0) pmol*100g ti ssue-1*min-1, P=1.000 vs. zero fl ux] and obese [0.70(-4.9–1.7) 
pmol*100g ti ssue-1*min-1, P=0.917 vs. zero fl ux]. 
Following ß-adrenergic sti mulati on plasma (arterialized) 25(OH)D3 level was not 
signifi cantly increased in lean [baseline: 56.1(16.0–84.5) vs. isoprenaline 55.0(17.4–80.0), 
P=0.499] (Fig.1A) or obese men [baseline: 49.6(33.5–63.4) vs. 49.3(34.6–64.6), P=0.917] 
(Fig.1B). In line, ß-adrenergic sti mulati on did not signifi cantly induce net 25(OH)D3 release 
across abdominal SAT in lean [-1.9(-10.8–3.2) pmol*100g ti ssue-1*min-1, P=0.208 vs. zero 
fl ux] (Fig.1C) and obese [-3.4(-12.1–2.4) pmol*100g ti ssue-1*min-1, P=0.249 vs. zero fl ux] 
(Fig.1D).
Figure 1. Panel a and b depict plasma (arterialized) Vitamin D 25(OH) D3 concentrati on at baseline and following 
ISO in lean (n = 8) and obese (n = 6). Net vitamin D 25(OH)D3 release (fl ux) across abdominal SAT in lean (Panel c) 
and obese (Panel d)
Vitamin D 1,25(OH)2D3 
Plasma arterialized 1,25(OH)2D3 did not diff er between lean and obese individuals 
at baseline (96.6(60.7–185.7) vs 108.2(80.5–147.7) pmol/L, respecti vely, P=0.755). 
Furthermore, no net 1,25(OH)2D3 release across SAT was observed under baseline 
conditi ons in lean [0.00(-0.01–0.03) pmol*100g ti ssue-1*min-1, P=0.889 vs. zero fl ux] and 
obese men [0.00(-0.09–0.00) pmol*100g ti ssue-1*min-1, P=0.345 vs. zero fl ux]. Following 
ß-adrenergic sti mulati on plasma (arterialized) 1,25(OH)2D3 was not signifi cantly increased 
in lean [baseline: 96.6(60.7–185.7) vs. isoprenaline 97.0(51.9–165.2), P=0.889] (Fig.2A) or 
obese men [baseline: 108.2(80.5–147.7) vs. 111.1(90.1–139.3), P=0.528] (Fig.2B). However, 
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the ISO induced change in 1,25(OH)2D3 fl uxes was signifi cantly diff erent between groups 
(P=0.007). An increased net 1,25(OH)2D3 release across abdominal SAT was observed in 
lean [ISO: -0.01(-0.04–0.00), P=0.017 vs. zero fl ux] (Fig.2C), but not in obese men [ISO: 
0.01(0.00–0.02), P=0.116 vs. zero fl ux] (Fig.2D).
Figure 2. Plasma (arterialized) vitamin D 1,25(OH)2D3 concentrati on at baseline and following ISO in lean (Panel a) 
versus obese (Panel b). Net vitamin D 1,25(OH)2D3 release (fl ux) across abdominal SAT in lean (Panel c) and obese 
(Panel d). 
(*) p < .05 versus zero fl ux.
Relati onship between AT lipolysis and vitamin D (arterialized) concentrati ons
Figure 3. Total glycerol release across abdominal SAT at baseline and during ß-adrenergic sti mulati on in lean (n = 8) 
versus obese (n = 6). Total glycerol release following ß-adrenergic sti mulati on was signifi cantly higher in lean (Panel 
a) versus obese (Panel b). (*) p < .05 
 Next, we investi gated whether the observed vitamin D release across SAT was 
associated with changes in local lipolyti c responses and systemic vitamin D concentrati on. 
As reported previously, a blunted ß-adrenergic mediated increase in total glycerol release 
across abdominal SAT was observed in obese [glycerol baseline vs. ISO obese: 143.9(114.4–
373.5) vs. 260.5(213.2–526.1) nmol.100g ti ssue-1.min-1; (P=0.11, Fig.3B)] compared to 
lean men [glycerol baseline vs. ISO lean: 209.6(170.8–460.2) vs. 474.8(250.8–1678.2) 
nmol.100g ti ssue-1.min-1); (P=0.01, Fig.3A)]. However, in present study, net vitamin D 
1,25(OH)2D3 release (fl ux) was not correlated with plasma (arterialized) glycerol levels 
during ß-adrenergic sti mulati on nor with circulati ng (arterialized) non-esterifi ed fatt y acid 
(NEFA) and 1,25(OH)2D3 levels. (P>0.05 for all, Supplemental Table S1).
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Discussion
 Obesity is often associated with vitamin D deficiency, which has been suggested to 
relate to insulin resistance and an impaired metabolic health (4). Recent studies in humans 
have demonstrated that vitamin D (including its metabolites)  accumulates and might be 
metabolised in adipose tissue (17-19). It has been shown that at least 35% of circulating 
vitamin D is likely sequestered in human subcutaneous adipose tissue (20). It was recently 
demonstrated that beside vitamin D uptake by adipose tissue there also can be significant 
release both in mice as well as human adipocytes (21). The latter findings suggest that 
beside an increased sequestration of vitamin D in AT, also an impaired release (22), may 
contribute to the accumulation of vitamin D in adipose tissue and to the often observed 
reduced circulating vitamin D concentrations in obesity.
 In the present study, we investigated in vivo fluxes of 25(OH)D3 and 1,25(OH)2D3 
across abdominal SAT for the first time after an overnight fast and during short-term 
ß-adrenergic stimulation in lean and obese men using the arterio-venous balance 
methodology. We observed that net vitamin D 1,25(OH)2D3 release across abdominal SAT 
during ß-adrenergic stimulation was significantly higher in lean as compared to obese men, 
suggesting a blunted vitamin D 1,25(OH)2D3 release across abdominal SAT in obese men in 
vivo. In contrast, no significant 25(OH)D3 release across SAT was observed in lean or obese 
men following an overnight fast or during ß-adrenergic stimulation. The latter findings may 
be in contrast with recent ex vivo data, which showed a more pronounced reduction in 
25(OH)D3 content in SAT derived adipocytes in lean compared to obese donors following 
adrenaline stimulation, possibly pointing towards a blunted 25(OH)D3 release in obese SAT 
(22). Unfortunately, in that study only measured vitamin D 25(OH)D3 tissue content and not 
25(OH)D3 or release in the medium. By using ex vivo cultures, the adipocytes are withdrawn 
from their natural local hormonal microenvironment, which may also partly explain the 
differences with the present in vivo findings. 
 The reason for the blunted SAT release of 1,25(OH)2D3 and not 25(OH)D3 in obese 
individuals remains to be determined. Factors like variation in ATBF theoretically resulting in 
a differential supply of vitamin D carriers to SAT or differences in circulating NEFA, interfering 
with the binding of vitamin D to its carrier could possibly explain the difference in vitamin D 
release. However, the ISO-induced increase in blood flow as well as circulating NEFA were 
not different between groups. Moreover, the above mechanisms would not explain why 
the differential release is only observed for 1,25(OH)2D3  and not for 25(OH)D3. Vitamin D 
1,25(OH)2D3 is a ligand for vitamin D receptor (VDR), and it has been shown that vitamin 
D receptor (VDR) expression is increased in SAT of individuals with obesity (23). From the 
latter, it could be speculated that vitamin D 1,25(OH)2D3 binds to a higher extent to VDR 
within SAT in individuals with obesity, resulting in less spillover of vitamin D 1,25(OH)2D3 in 
the circulation in obese individuals but not in lean, which still needs further investigation.
 Of interest, the observed blunted release of 1,25(OH)2D3 across abdominal SAT that 
we found in the present study was accompanied by (but not correlated with) a blunted 
glycerol release in SAT of obese men. The latter finding as well as the fact that the blunted 
lipolysis only coincides with a blunted release of 1,25(OH)2D3 and not 25(OH)D3 does not 
support the idea that it is in the obese individuals observed impaired TAG hydrolysis that 
drives a blunted release of vitamin D metabolites. The exact relationship between the 
impaired ISO-induced lipolysis and 1,25(OH)2D3 release and to what extent they are co-
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regulated remains to be determined.
 Furthermore, although net 1,25(OH)2D3 release was observed during acute 
ß-adrenergic stimulation, no changes in plasma vitamin D 1,25(OH)2D3  (arterialized) 
concentration were observed. It is likely that following this short-term (1 hour) ISO infusion, 
the contribution of 1,25(OH)2D3 release per unit adipose tissue may be relatively too small 
to induce significant changes in circulating vitamin D concentrations. We have estimated 
this based on several assumptions for the amount of total body water (72% of fat free mass 
and 10% of fat mass is water) and extra cellular water (38% of total body water) (24) and 
we took into account the half-life of 1,25(OH)2D3 (25). Based on these assumptions, the 
estimated percentage contribution of total vitamin D 1,25(OH)2D3 release across adipose 
tissue to plasma concentrations during isoprenaline stimulation ranged between 0 and 4%. 
This relatively small contribution might partly explain why no significant increase in plasma 
vitamin D 1,25(OH)D3 after ß-adrenergic stimulation was observed in the present study. 
 We have measured vitamin D 25(OH)D3 and 1,25(OH)2D3 metabolites based on their 
proposed importance in human metabolism and health (26). However, there are several 
other vitamin D metabolites such as 24,25-dihydroxyvitamin D [24,25(OH)2D3] (27) and 
3-epi-25(OH)D (28). The role of the latter vitamin D metabolite  (29) in human is currently 
unknown and warrants investigation. A limitation of the study is that we were, unfortunately, 
unable to measure adipose tissue vitamin D content, which would be interesting to take into 
account in future studies. Whether long-term interventions that activate SAT lipolysis and 
vitamin D release (e.g. weight loss (30) and exercise (7)) might affect circulating vitamin D 
concentrations needs to be investigated in more detail. In conclusion, our unique in vivo 
data show that ß-adrenergic stimulation induces release of active vitamin D metabolite 
across abdominal SAT. In the present study, a blunted catecholamine-mediated lipolysis was 
accompanied by a decreased 1,25(OH)2D3 (active metabolite) release across abdominal SAT 
in obese men. Future studies are warranted to elucidate to what extent this blunted vitamin 
D release may affect circulating vitamin D concentrations in obese humans.
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Supplemental Table S1. Spearman correlation coefficient between net vitamin D release 
and arterialized glycerol, arterialized NEFA levels, arterialized vitamin D 1,25(OH)2D3 during 
ISO concentrations.
Arterialized Glycerol Arterialized NEFA Arterialized 1,25(OH)2D3
1.25(OH)2D3 flux during 
ISO-stimulation 0.402 (P=0.154) 0.341 (P=0.233) 0.240 (P=0.409)
Data are presented as correlation coefficient (P value).
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Abstract
Context: Vitamin D deficiency in obesity has been linked to insulin resistance. However, 
studies that examined the association between plasma 25-hydroxyvitamin D3 [25(OH)D3] as 
well as plasma 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and tissue-specific insulin sensitivity 
are scarce. Furthermore, vitamin D receptor (VDR) and vitamin D-metabolizing enzymes 
(CYPs) expression in adipose tissue (AT) might affect AT insulin sensitivity.
Objective: To investigate the association between BMI and plasma 25(OH)D3, plasma 
1,25(OH)2D3, and AT VDR; between plasma 25(OH)D3 ,1,25(OH)2D3, and AT VDR and tissue-
specific insulin sensitivity in overweight/obese individuals.
Design and Patients: This analysis included 92 adult individuals (BMI: >25 kg/m2). A two-
step hyperinsulinemic-euglycemic clamp with a [6,6-2H2]-glucose tracer was performed to 
assess tissue-specific insulin sensitivity. Abdominal subcutaneous AT (SAT) mRNA expression 
of VDR and CYP was determined using qRT-PCR. 
Setting: University Medical Centre.
Main Outcome Measures: Plasma 25(OH)D3, 1,25(OH)2D3, 1,25(OH)2D3/25(OH)D3 ratio, SAT 
AT VDR and CYPs mRNA, and tissue-specific insulin sensitivity.
Results: BMI was inversely associated with plasma 25(OH)D3 (ß= -0.274, P=0.011) but not 
with plasma 1,25(OH)2D3. Plasma 25(OH)D3 was not related to CYPs or VDR expression in SAT. 
Plasma 1,25(OH)2D3 and 25(OH)D3 were not related with tissue-specific insulin sensitivity. 
Interestingly, SAT VDR mRNA was negatively associated with AT insulin sensitivity (ß= -0.207, 
P=0.025),
Conclusions: BMI was inversely associated with 25(OH)D3 concentrations, which could not 
be explained by alterations in SAT VDR and CYP enzymes. Plasma vitamin D metabolites 
were not related to tissue-specific insulin sensitivity. However, VDR expression in SAT was 
negatively associated with AT insulin sensitivity.
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Introduction
 Obesity has reached epidemic proportions in both developed and developing 
countries (1). Body fat accumulation and in particular an impaired adipose tissue (AT) 
function, which is commonly observed in obesity, has been linked to the development of 
metabolic syndrome, insulin resistance, type 2 diabetes and cardiovascular diseases (2, 3). 
Of interest, obesity is often characterized by low plasma 25-hydroxyvitamin D3 [25(OH)D3] 
levels (<50 nmol/L). This plasma vitamin D deficiency in obese individuals has been suggested 
to contribute to obesity-related metabolic disorders such as insulin resistance and type 2 
diabetes (4, 5). However, evidence from human observational data is not consistent. Recent 
studies have shown a negative association between plasma or serum vitamin D 25(OH)D3 
levels and whole-body insulin resistance, as estimated from the Homeostatic Model for 
Insulin Resistance (HOMA-IR), which was independent of body mass index (BMI) in both 
men and women (6, 7). In contrast, other studies have shown no association between 
serum 25(OH)D3 and insulin resistance (HOMA-IR) in obese humans (8, 9). It has been 
hypothesized that mainly adiposity itself may determine the observed relationship between 
plasma vitamin D deficiency and insulin resistance, due to sequestration of vitamin D in the 
enlarged AT mass (10). Furthermore, it has been proposed that the difference in vitamin D 
concentrations between lean and obese individuals may be explained by volumetric dilution 
in obesity, with body weight explaining 13% of the variance in vitamin D concentrations (11). 
Finally, it has been postulated that an altered vitamin D metabolism in AT may contribute to 
vitamin D deficiency and insulin resistance (12).
 Indeed, AT is actively involved in vitamin D metabolism, which is underlined by the 
expression of vitamin D-metabolizing enzymes (CYP) and the vitamin D receptor (VDR) in 
AT (13). The vitamin D receptor (VDR) belongs to the nuclear receptor family and mediates 
effects of vitamin D at the gene transcription level (14). In murine adipocytes, the active 
vitamin D metabolite (1,25(OH)2D3) may increase sirtuin 1 (SIRT1) and the  NAD
+/NADH, 
thereby affecting cellular energy metabolism (15). Furthermore, it has previously been 
reported that VDR expression is comparable in visceral AT (VAT) and subcutaneous AT (SAT) 
of obese individuals (16), although the expression of vitamin D-metabolizing enzymes 
(CYP) was decreased in SAT of obese individuals (16). Currently, it is not clear whether 
VDR expression is altered in the obese insulin resistant state and whether alterations in AT 
expression of VDR or vitamin D metabolizing enzymes relate to vitamin D deficiency and/or 
AT insulin resistance. Recent meta-analyses have shown that vitamin D supplementation had 
no significant effects on whole-body insulin resistance and insulin secretion in overweight/
obese individuals (17, 18). Taken together, the contribution of vitamin D deficiency to 
whole-body and tissue-specific insulin resistance remains to be established, and it is unclear 
whether a possible association is independent of body mass index (BMI) and/or body fat 
percentage (19, 20). Moreover, most studies that examined the association between vitamin 
D and insulin sensitivity did not use the gold-standard hyperinsulinemic euglycemic clamp 
to determine insulin sensitivity (21). Additionally, most of the studies on the relationship 
between vitamin D and insulin sensitivity have measured the inactive metabolite of vitamin 
D, 25(OH)D3  (7, 9, 22), instead of its active metabolite, 1,25(OH)2D3 or the active/inactive 
metabolite ratio. Finally, data on AT vitamin D metabolism in the obese insulin resistant state 
is scarce. 
 Therefore, in the present study, we investigated vitamin D metabolites (both inactive 
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and active forms) as well as AT expression of genes involved in vitamin D metabolism in 
overweight/obese men and women who underwent a 2–step hyperinsulinemic euglycemic 
clamp with a [6,6-2H2]-glucose tracer to investigate adipose tissue, liver and skeletal muscle 
insulin sensitivity. Firstly, we investigated whether obesity (BMI) is related to plasma active, 
inactive vitamin D concentrations or the ratio between both. Subsequently, we investigated 
whether putative alterations in plasma vitamin D metabolites in obesity may be mediated 
by an altered expression of AT VDR or vitamin D-metabolizing enzymes. Secondly, we 
investigated whether plasma vitamin D and AT expression of VDR relates to tissue-specific 
insulin sensitivity and, if so, whether these relationships are independent of BMI, age and 
sex. Finally, we investigated whether an altered AT vitamin metabolism may relate to AT 
insulin sensitivity.
Subjects and Methods
Subjects
 The study participants were men and women with Caucasian ethnicity, recruited 
at the Maastricht University Medical Center+, Maastricht, The Netherlands. Inclusion and 
exclusion criteria of these participants are described elsewhere in more detail (23, 24). The 
subjects gave written informed consent for their participation, and the study was reviewed 
and approved by the local Medical Ethical Committee of Maastricht University Medical 
Center+. 
Two-step hyperinsulinemic-euglycemic Clamp 
 A two-step hyperinsulinemic–euglycemic clamp combined with a [6,6-2H2]-glucose 
tracer (Cambridge Isotope Laboratories) was performed to analyze the insulin-mediated 
suppression of Free Fatty Acids (FFAs; representing AT insulin sensitivity) (25), insulin-
stimulated rate of disappearance (Rd) of glucose (peripheral/muscle insulin sensitivity), 
and insulin-mediated suppression of Endogenous Glucose Production (EGP) (hepatic 
insulin sensitivity) (26). A bolus injection of 2.4 mg [6,6-2H2]-glucose/kg was administered, 
continued with [6,6-2H2]-glucose infusion at 0.04 mg/ (kg x min). After 2 hr, low-dose insulin 
was infused at 10 mU/m2/min for 2 hr (27), followed by high-dose insulin at 40 mU/m2/min 
for 2 hr (28). By variable co-infusion of a 17.5% glucose solution, enriched by 1.1% tracer, 
plasma glucose concentrations were maintained at 5.0 mmol/l. For calculation of steady-
state kinetics, additional blood samples were taken in the last 30 min of each step (0, 10, and 
40 mU/m2/min insulin) (23). The Rd was calculated during the 0 and 40 mU/m2/min insulin 
infusion, whereas calculations for insulin-mediated suppression of EGP and free fatty acids 
was performed during 0 and 10 mU/m2/min insulin infusion, as relative percentage (%) of 
suppression during 10 compared with 0 mU/m2/min (24). Blood samples were taken from a 
superficial dorsal hand vein, which was arterialized by using a hot-box (~50oC).
Adipose Tissue Biopsy and Analysis
 An abdominal subcutaneous AT biopsy was taken under local anesthesia following 
an overnight fast, as described before (23). The AT sample was washed in sterile saline, 
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immediately frozen in liquid nitrogen, and maintained at - 80°C until further analysis. For 
RNA isolation, the tissue was placed in Trizol (Qiagen) and then mixed by means of an ultra 
turrax homogenizer. Total RNA was extracted using phenol-chloroform extraction method 
and described in more detail elsewhere (16).
Adipose tissue gene expression
 For real-time quantitative PCR, cDNA was generated using an iScript cDNA synthesis 
kit, according to the instructions of the manufacturer (Bio-Rad Laboratories). PCR-master 
mix, containing the specific primers, was added and real-time quantification of genes was 
performed by SYBR-green real-time reverse transcription PCR assay (Bio-Rad iQ SYBR green 
mix) using a MyIQ Real time PCR cycler (Bio-Rad). The primer pairs that were used are 
described in Supplemental Table S1. 18S was used as a housekeeping gene and data were 
calculated using delta CT method (16).
Biochemical analysis
 Blood was collected into pre-chilled tubes and centrifuged at 1,000 g, and 
plasma was snap-frozen and stored at ~80oC until analyses. Tracer enrichment of rate of 
disappearance (Rd) and endogenous glucose production (EGP) were determined using 
gas chromatography-mass spectrometry (26). Plasma glucose and FFA were determined 
using commercial available colorimetric assays on a Cobas Fara auto-analyzer (Roche, 
Switzerland). Plasma insulin was measured with a double-antibody radioimmunoassay 
(Millipore). Plasma concentrations of vitamin D 25(OH)D3 and 1,25(OH)2D3 were determined 
using liquid-chromatography tandem-mass spectrophotometry (LC-MS/MS), as described 
before (29).
Statistical Analysis
 All continuous variables were checked for normal distribution. Variables with a 
skewed distribution were square root transformed (plasma vitamin D concentration and 
SAT VDR mRNA) or natural logarithmic (ln) transformed (SAT vitamin D enzymes, CYP2J2, 
CYP27A1, CYP27B1, and CYP24A1) to satisfy condition of normality.  
First, simple regression analysis was performed with plasma vitamin D metabolites 
or VDR and vitamin D-metabolizing enzymes as dependent variables, and BMI as independent 
variable. Subsequently, multiple regression analysis was performed with age and sex added 
as independent variables. 
Secondly, simple regression analysis was performed with hepatic, peripheral, 
or AT insulin sensitivity as dependent variables, and plasma 25(OH)D3,1,25(OH)2D3 or 
1,25(OH)2D3/25(OH)D3 ratio as independent variables (Model 1). Next, BMI, age, and sex 
were added to the model as independent variables (Model 2). Finally, simple regression 
analysis was performed to relate SAT VDR gene expression and AT insulin sensitivity. 
Subsequently, multiple regression analysis was conducted to test whether SAT VDR gene 
expression might relate to AT insulin sensitivity, independent of age, BMI and sex. Interaction 
between covariates in the multiple regression analyses was also tested, and no interaction 
was found. All data were analyzed using SPSS for Mac version 22.0 (SPSS, Chicago, IL, USA) 
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and statistical significance was set at p < 0.05.
Results
Characteristics of study participants
 Anthropometric and metabolic characteristics for all participants are presented in 
Table 1. The majority of study participants were men (78.3%), with age ranged between 
19 and 69 years, and BMI ranged between 25.4 and 38.6 kg/m2. The mean plasma 25(OH)
D3 (inactive metabolite) concentration was 56.0 nmol/L (range: 12.6 - 122.6 nmol/L), with 
45.7% of all participants (n=42) classified as vitamin D deficient, based on the Endocrine 
Society cut off (< 50 nmol/L) (30).
Table 1. Characteristics of the Study Participants (n = 92)
Variable Mean + SD Range
Age (years) 50.3 + 13.6 19 - 69
Sex (Males/Females) 72 M / 20 F
BMI (kg/m2) 30.6 + 2.9 25.4 – 38.6
Waist circumference (cm) 103 + 12 77 – 126
W/H ratio 0.9 + 0.1 0.7 – 1.2
Fasting insulin (mU/l) 13.9 + 6.8 2.8 – 30.3
Fasting glucose (mmol/l) 5.6 + 0.6 4.4 – 7.5
2h-glucose (mmol/l) 6.5 + 1.8 3.4 – 11.2
HOMA-IR 3.6 + 1.9 0.7 – 8.8
Insulin-mediated suppression of EGP (%) 50.6 + 18.9 5.2 – 97.9
Insulin-mediated suppression of FFA (%) 52.9 + 20.3 6.1 – 90.6
Insulin-stimulated Rd (µmol kg-1 min-1) 27.0 + 10.8 9.8 – 53.9
25(OH)D3 (nmol/L, inactive metabolite) 56.0 + 21.6 12.6 – 122.6
1,25(OH)2D3 (pmol/L, active metabolite) 106.3 + 26.4 54.9 – 205.0
The active/inactive metabolite ratio 2.2 + 0.9 1.0 – 6.5
Unless otherwise noted, values are the mean 6 SD. All participants were Caucasian. Abbreviations: EGP, endogenous 
glucose production; FFA, free fatty acid; HOMA-IR, homeostasis model assessment insulin resistance; Rd, rate of 
glucose disappearance.
Association between BMI and plasma vitamin D concentration
Table 2. Determinants of plasma 25(OH)D3, 1,25(OH)2D3 and the 1,25(OH) 2D3/25(OH)D3 ratio
 BMI was negatively associated with plasma 25(OH)D3 (std ß = -0.234, 95%CI 
-0.44 (-0.02), P=0.031), but did not relate with plasma 1,25(OH)2D3 and the ratio. Multiple 
regression analysis showed that the relationship between BMI and plasma 25(OH)D3 
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remained significant after adjustment for age and sex (std ß= -0.274, P=0.011) (Table 2). 
Association between BMI and vitamin D-related gene expression in SAT
 BMI was positively associated with SAT VDR gene expression (std ß =0.223, 95%CI 
0.00 (0.44), P=0.047, Table 3). It is well established that VDR expression is regulated by 
1,25(OH)2D3 (31). However, the strength of the association between BMI and AT VDR gene 
expression did not change (std ß = 0.213, 95%CI -0.11 (0.44), P=0.062) after adjustment for 
plasma 1,25(OH)2D3 (active metabolite), age and sex. No significant associations were found 
between BMI and SAT expression of vitamin D metabolizing enzymes (CYP2J2, CYP27A1, 
CYP27B1, CYP24A1) (Supplemental Table S2). 
Table 3. Determinants of vitamin D receptor expression in abdominal SAT
SAT VDR gene expression
ß 95% CI P value Adj. R2
Model 1
BMI 0.223 0.00 (0.44) 0.047 0.036
Model 2
BMI 0.213 -0.11 (0.44) 0.062 0.138
Plasma 1,25(OH)2D3 0.019 -0.19 (0.23) 0.855
Age 0.251 -0.01 (0.51) 0.057
Sex :
     Men 0 0  
     Women -0.327 -0.99 (0.34) 0.332
Plasma vitamin D 25(OH)D3 and SAT expression of VDR and vitamin D enzymes 
Table 4. Relationship between plasma vitamin D deficiency and SAT expression of VDR and 
Vitamin D-Metabolizing enzymes
Plasma 25(OH)D3
(inactive metabolite)
ß 95% CI P Value Adj. R2
Model 1
BMI -0.234 -0.44 (-0.02) 0.031 0.043
Model 2
BMI -0.234 -0.48 (0.09) 0.059 0.028
SAT VDR mRNA 0.142 -0.09 (0.38) 0.232
Model 3
BMI -0.252 -0.54 (0.03) 0.083 0.018
CYP2J2 mRNA 0.022 -0.23 (0.28) 0.861
Model 4
BMI -0.254 -0.52 (0.01) 0.061 0.029
CYP27A1 mRNA 0.105 -0.13 (0.34) 0.373
Model 5
BMI -0.189 -0.48 (0.10) 0.203 0.009
CYP27B1 mRNA 0.139 -0.12 (0.39) 0.282
Model 6
BMI -0.248 -0.54 (0.04) 0.092 0.021
CYP24A1 mRNA 0.079 -0.18 (0.33) 0.539
 Next, we investigated the relationship between plasma 25(OH)D3 levels and the 
expression of VDR and enzymes related to vitamin D metabolism in SAT. Abdominal SAT 
expression of VDR and vitamin D-metabolizing enzymes was not associated with plasma 
25(OH)D3 level (Supplemental Table S3). Additionally, we investigated whether the 
negative relationship between BMI and plasma 25(OH)D3 may be mediated by alteration 
in AT expression of VDR or vitamin D-metabolizing enzymes. As indicated in Table 4, 
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further adjustment for SAT VDR expression or SAT vitamin D metabolizing enzymes did not 
significantly alter the relationship between BMI and plasma 25(OH)D3.
Plasma vitamin D metabolite levels and tissue-specific insulin sensitivity  
 Neither plasma 25(OH)D3 (inactive metabolite) nor plasma 1,25(OH)2D3 (active 
metabolite) or the active/inactive metabolite ratio were associated with hepatic, peripheral 
or AT insulin sensitivity, as shown in Table 5.
Table 5. Relationship between plasma vitamin D metabolites and hepatic, peripheral, 
adipose tissue insulin sensitivity
Models 2 to 4 include BMI, age, and sex; model 2 includes plasma 25(OH)D3; model 3 includes plasma 1,25(OH)2D3; 
Model 4 includes ratio vitamin D instead of plasma 25(OH)D3 and 1,25(OH)2D3 in addition to independent variables 
BMI, age, and sex. Abbreviation: IS, insulin sensitivity. 
Subcutaneous AT VDR, vitamin D-metabolizing enzyme expression and adipose tissue 
insulin sensitivity
Table 6. Relationship between SAT VDR expression and adipose tissue insulin sensitivity
Adipose Tissue Insulin Sensitivity
ß 95% CI PValue Adj. R
2
Model 1
SAT VDR mRNA -0.366 -0.56 (-0.17) <0.001 0.140
Model 2
SAT VDR mRNA -0.207 -0.39 (-0.03) 0.025 0.369b
BMI -0.169 -0.34 (0.05) 0.057
Age 0.036 -0.17 (0.25) 0.729
Sex:
     Men 0 0
     Women 1.176 0.64 (1.71) <0.001
 Finally, the association between AT VDR gene expression and AT insulin sensitivity 
was examined. SAT VDR expression was negatively correlated with AT insulin sensitivity (std 
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ß = -0.207, 95% CI -0.39 (-0.03), P=0.025), which was independent of age, sex, and BMI 
(Table 6). No associations were found between SAT expression of vitamin D-metabolizing 
enzymes and AT insulin sensitivity (data not shown).
Discussion
 In the present study, we demonstrated for the first time that (1) BMI was negatively 
associated with of plasma 25(OH)D3 but not with plasma 1,25(OH)2D3, nor its ratio; (2) Plasma 
vitamin D 25(OH)D3 deficiency was neither related to changes in SAT vitamin D-metabolizing 
enzymes nor SAT VDR gene expression; (3) plasma 25(OH)D3, 1,25(OH)2D3, and the active/
inactive metabolite ratio were not significantly associated with hepatic, peripheral or AT 
insulin sensitivity, (4) SAT VDR gene expression was negatively associated with AT insulin 
sensitivity.
 We found that BMI was one of the major determinants of plasma 25(OH)D3 
concentration (inactive metabolite), whilst BMI was neither associated with plasma 
1,25(OH)2D3 concentration (active metabolite) nor with the active/inactive metabolite 
ratio. This might be explained by the increased leptin concentrations in obese individuals, 
which may suppress renal conversion of vitamin D 25(OH)D3 to 1,25(OH)2D3 indirectly by 
stimulation of osteoblast and/or osteocyte FGF23 production (32). In line, a recent large 
meta-analysis, which included 21 adult cohorts, clearly demonstrated that a higher BMI is 
accompanied by lower 25(OH)D3 status (33). In addition, previous data in morbidly obese 
women has also shown that BMI was inversely related with 25(OH)D3 level but not with 
1,25(OH)2D3 (29). It has been postulated that these low plasma 25(OH)D3 levels in obese may 
be partly explained by increased blood volume due to the larger body size(i.e. volumetric 
dilution) or sequestration of vitamin D in the expanded body fat depot (10, 11). However, 
vitamin D may affect skeletal muscle mass (34) as well as bone mass (35). Therefore, it is 
important to distinguish between the relationship between vitamin D and BMI or adipose 
tissue mass. Unfortunately, in the present study we did not assess body composition. 
Therefore, it is unclear whether the observed association between Vitamin D and BMI 
reflects the relationship with adipose tissue mass per se. The latter needs to be investigated 
in more detail in future research.
 Alterations in AT vitamin D metabolism might be implicated in plasma vitamin 
D deficiency (36). However, in the present study, we did not find a significant association 
between SAT VDR gene expression and plasma 25(OH)D3 concentration. Furthermore, the 
expression of the vitamin D-metabolizing enzymes (CYP) in SAT was not significantly related 
to plasma 25(OH)D3 levels. In contrast, previous finding have shown a positive correlation 
between CYP27A1 expression in VAT and plasma 25(OH)D3 (16). In addition, Wamberg et 
al.(16) showed that obesity is characterized by a decreased expression of the 25-hydroxylase 
CYP2J2 and the 1a-hydroxylase CYP27B1 in SAT. Whereas the catabolic CYP24A1 does not 
differ between lean and obese women. However, the expression of catabolic CYP24A1 
increased after weight loss (16), suggesting a higher vitamin D turnover in the SAT of 
obese subjects following weight loss.  We cannot exclude that gene expression of vitamin 
D-metabolizing enzymes may be different between the SAT and VAT (16), which might partly 
explain the lack of association between plasma 25(OH)D3 with SAT gene expression in the 
present study. In the present study, SAT VDR expression was positively associated with BMI 
which is in line with previous findings in VAT (7), indicating that VDR expression is increased 
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in both SAT and VAT in obesity. However, the physiological relevance of this upregulation 
needs to be elucidated in future research. The SAT is by far the body’s largest fat depot, and 
an important mass effect on vitamin D metabolism, is therefore, more likely compared to 
the VAT. 
 Recent meta-analyses have shown no effect of oral vitamin D3 supplementation 
on glucose metabolism and insulin resistance/secretion (17, 37). Here, we found that 
plasma 25(OH)D3, 1,25(OH)2D3 concentration, and the 1,25(OH)2D3/25(OH)D3 ratio were 
not significantly associated with hepatic, peripheral, or AT insulin sensitivity in overweight/
obese men and women. Taken together, our data suggest that plasma vitamin D deficiency 
is not related to insulin resistance in overweight/obese men and women, assessed using 
the gold-standard hyperinsulinemic-euglycemic clamp. Finally, we observed that higher 
SAT VDR gene expression was associated with lower AT insulin sensitivity independent of 
BMI, age, and sex, and explained 14% of the variance in AT insulin sensitivity. Recent study 
has suggested that the association between insulin resistance related diseases and VDR 
polymorphisms was more pronounced in dark-pigmented Caucasians and Asians but not 
in white-pigmented Caucasian (38). However, it needs to be investigated whether these 
genetic and our observed transcriptional differences also translate into functional changes 
at the protein level. Furthermore, it has been shown that VDR mRNA expression is positively 
associated with local inflammation in human SAT and VAT (39).  However, further studies are 
needed to investigate whether the observed association between SAT VDR expression and 
AT insulin sensitivity is at least partly explained by AT inflammation.
In conclusion, obesity is associated with lower plasma 25(OH)D3 (inactive 
metabolite), but not with plasma 1,25(OH)2D3 (active metabolite) nor 1,25(OH)2D3/25(OH)
D3 ratio. This plasma vitamin D deficiency was not related changes in AT expression of 
vitamin D metabolizing enzymes (CYP) nor VDR. Neither plasma 25(OH)D3, 1,25(OH)2D3 
concentration or 1,25(OH)2D3/25(OH)D3 ratio were associated with hepatic, adipose tissue, 
and peripheral insulin sensitivity in overweight/obese men and women. Interestingly, SAT 
VDR gene expression was negatively associated with AT insulin sensitivity, and future studies 
are needed to unravel the molecular mechanisms by which nuclear and membrane-bound 
VDR interact with insulin action in abdominal SAT.
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Supplemental Tables
Supplemental Table S1. Primer sets used for real time PCR
Genes Primers (forward) Primers (reverse)
VDR 5’- GGCCCAACTCCAGACACACT-3’ 5’-GGGTCACAGAAGGGTCATCTGA-3’
CYP2J2 5’-TCCATCCTCGGACTCTCCTAC-3’ 5’-GCGCCGTCTTTTGAGAAAGT-3’
CYP27A1 5’-CGGCAACGGAGCTTAGAGG-3’ 5’-GGCATAGCCTTGAACGAACAG-3’
CYP27B1 5’-GAGACTGGGACCAGATGTTTG-3’ 5’-CAGGCAACTCTTCCCGGAAC-3’
CYP24A1 5’- GGTGGCGAGACTCAGAACG-3’ 5’- GTCGTGCTGTTTCTTGAGACC-3’
18S 5’-AGTTAGCATGCCAGAGTCTGG-3’ 5’-TGCATGGCCGTTCTTAGTTG-3’
Supplemental Table S2. Determinants of subcutaneous AT vitamin D-metabolizing enzymes 
mRNA
Supplemental Table S3.  Relationship between SAT vitamin D metabolizing enzymes and 
plasma inactive vitamin D concentration
Plasma 25(OH)D3 
(inactive metabolite)
ß 95% CI P
CYP2J2 mRNA -0.011 -0.27 (0.24) 0.930
CYP27A1 mRNA 0.080 -0.16 (0.32) 0.506
CYP27B1 mRNA 0.122 -0.13 (0.38) 0.345
CYP24A1 mRNA 0.077 -0.18 (0.34) 0.555
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Abstract
Background: Vitamin D has been suggested to affect peripheral insulin sensitivity. Evidence 
regarding the effect of vitamin D supplementation on insulin sensitivity is still conflicting. 
Purpose: This meta-analysis aimed to assess the effect of vitamin D supplementation on 
insulin sensitivity in humans with or at risk of insulin resistance. 
Data source and study selection: PubMed, Web of Science, Embase, CINAHL, and Cochrane 
library were systematically searched for randomized controlled trials (RCTs) from 1980 until 
31 December 2018, reporting treatment effects of vitamin D supplementation on insulin 
sensitivity. 
Data extraction: The main outcome of interest was the change in insulin sensitivity, derived 
from the gold standard hyperinsulinemic euglycemic clamp or the Matsuda index derived 
from Oral Glucose Tolerance Test (OGTT) and insulin sensitivity index from Intravenous 
Glucose Tolerance Test (IVGTT). We extracted data on the standardized mean difference 
(SMD) between the vitamin D treatment and placebo groups in change from baseline of 
insulin sensitivity.
Data synthesis: Eighteen RCTs were included in this meta-analysis comparing vitamin D 
supplementation (n= 612) with placebo (n=608). Vitamin D supplementation had no effect 
on insulin sensitivity (SMD: -0.01; 95% CI: -0.12, 0.10; P= 0.87, I2= 0%). Visual inspection of 
funnel plot symmetry did not suggest potential publication bias.
Limitations: The number of individuals who participated in the included studies was 
relatively small possibly due to the invasive character of the measurement (e.g. clamp).
Conclusions: This meta-analysis provides no evidence that vitamin D supplementation has a 
beneficial effect on peripheral insulin sensitivity in people with or at risk of insulin resistance.
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Introduction
 The International Diabetes Federation (1) has reported that the worldwide 
diabetes prevalence in the adult population reached 8.8% (424.9 million people) in 2017. 
The majority (87-91%) of these diabetes cases concerns type 2 diabetes. Type 2 diabetes 
has become a major public health concern due to its complications. It decreases quality of 
life and increases mortality risk (2). Additionally, about 7.3% of the adult population (352.1 
million people) suffers from prediabetes (1). Prediabetes is defined by increased fasting 
glucose and/or impaired glucose tolerance (postprandial hyperglycemia), which are both 
strongly associated with obesity (3). Moreover, postprandial hyperglycemia is a major risk 
factor for developing type 2 diabetes (4).
 Obesity, prediabetes, and type 2 diabetes are often characterized by low circulating 
levels of vitamin D (vitamin D deficiency) (5). Indeed, based on cross sectional studies, 
vitamin D deficiency has been linked with an impaired insulin sensitivity in humans (6). 
Furthermore, people with low vitamin D levels (7) may be at greater risk to develop type 2 
diabetes. Of interest, the vitamin D receptor, which mediates the function of vitamin D, is 
also expressed in insulin-sensitive tissues (including adipose tissue, muscle, and pancreas) 
(8-10). Therefore, currently non-skeletal functions of vitamin D in insulin-sensitive organs 
are being investigated.
 Several plausible mechanisms have been proposed to explain a potential role of 
vitamin D in improving insulin sensitivity (6, 11). In adipose tissue, vitamin D may affect lipid 
metabolism (12) and may reduce inflammation (13). Vitamin D may affect pancreatic insulin 
secretion via protection of beta-cells from local inflammation (14). Vitamin D may also affect 
insulin secretion, which is mediated by a calcium-dependent mechanism (15).  In addition, it 
has been demonstrated that vitamin D affects skeletal muscle metabolism, insulin sensitivity 
and lipid composition (16, 17). Thus, increasing circulating vitamin D concentration might 
be expected to have beneficial effects on tissue energy and substrate metabolism thereby 
contributing to an improvement of whole-body insulin sensitivity. 
 In recent years, several meta-analyses (18-23) have been conducted to investigate 
the effect of vitamin D supplementation on whole-body insulin sensitivity. However, the 
findings from these reports are inconsistent. From the six meta-analyses published between 
2015 and 2018, 4 studies (18-21) indicated insufficient evidence/no effect on glycemic 
control and insulin resistance whereas 2 studies (22, 23) indicated sufficient evidence for 
an improvement of glycemic control and insulin sensitivity. Moreover, these meta-analyses 
have been focusing only on glucose homeostasis under fasting conditions by studying 
parameters such as homeostatic model assessment of insulin resistance (HOMA-IR), fasting 
glucose, fasting insulin, and Glycated haemoglobin 1c (HbA1c) as main outcome measures. 
Of importance, the skeletal muscle is considered as an important organ in peripheral insulin 
sensitivity as it affects 70-90% of total glucose disposal under postprandial conditions 
(non-fasting conditions) (24, 25). Studies have shown that vitamin D may affect skeletal 
muscle substrate metabolism and insulin sensitivity (16, 17). Thus, increasing circulating 
vitamin D concentration by means of supplementation might be expected to have beneficial 
effects during postprandial conditions by improving skeletal muscle glucose handling/
insulin sensitivity. Therefore, we undertook a systematic review and meta-analysis of RCTs 
to delineate the impact of vitamin D supplementation on insulin sensitivity derived from 
the gold standard hyperinsulinemic euglycemic clamp or from a multi-sampled oral or 
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intravenous glucose tolerance tests (OGTT or IVGTT) as well as the postprandial glucose 
concentrati ons (OGTT) in humans with or at risk of insulin resistance. 
Methods
Literature search strategy and study selecti on
Figure 1. Flowchart diagram for study selecti on of systemati c review (based on Preferred Reporti ng Items for 
Systemati c Reviews and Meta-Analysis/PRISMA guideline)
 We conducted our systemati c review and meta-analysis according to the Preferred 
Reporti ng Items for Systemati c Reviews and Meta-Analyses (PRISMA) guidelines (26). The 
protocol for our systemati c review was registered at the Internati onal Prospecti ve Register 
of Systemati c Reviews, PROSPERO (registrati on CRD42018092961). The main outcome of 
interest was the change in insulin sensiti vity, derived from a gold standard hyperinsulinemic 
euglycemic clamp or in the form of the Matsuda Index derived from OGTT and/or insulin 
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sensitivity index derived from intravenous glucose tolerance test (IVGTT), subsequent to 
vitamin D administration in individuals with or at risk of insulin resistance. The secondary 
outcome was the change in 2-hour postprandial glucose concentration and/or area under 
the curve (AUC) glucose during an OGTT.
A comprehensive literature search’s [PubMed/Medline (Medical Literature 
Analyses and Retrieval System Online), Cochrane library, Web of Science, Embase database 
(OVID) and The Cumulative Index to Nursing and Allied Health Literature (CINAHL) was 
performed to identify articles from 1980 until 31 December 2018. The main keywords 
used were overweight, obesity, prediabetes, type 2 diabetes mellitus, vitamin D, insulin 
sensitivity, insulin resistance, blood glucose. These keywords were combined with Boolean 
operators (e.g. OR, AND, NOT), and all Fields or Medical subject subheading (MeSH) terms. 
This set of search terms was slightly modified when searching in every database due to a 
different system and technical limitations (Supplemental Table S1).
Eligible studies met the PICOS (Patients/participants, Intervention, Comparison/
control group, Outcome, and Study Design) criteria: (1) study was a randomized controlled 
trial; (2) study population consisted of individuals with elevated (risk for) insulin resistance 
(overweight, obesity, prediabetes, polycystic ovary syndrome (PCOS), and type 2 diabetes 
without complications); (3) participants were ≥ 18 years; (4) interventions were vitamin D 
supplementation vs the appropriate placebo; (5) vitamin D supplementation dose was daily, 
weekly, or monthly; (6) trial length was ≥ 2 months; (7) serum 25(OH)D level was measured; 
(8) insulin sensitivity was measured by Matsuda index derived from an OGTT and/or insulin 
sensitivity index derived from IVGTT, or by a hyperinsulinemic euglycemic clamp at the 
beginning and at the end of the trial; and (9) study was published in English. 
Following the search, duplicates were removed. A total of 18 studies were included 
in this systematic review (Figure 1). Exclusion criteria were as follows: (1) non clinical trial 
studies; (2) studies without outcome of insulin sensitivity derived from multi-sampled oral 
glucose tolerance test or hyperinsulinemic euglycemic clamp; (3) study populations with 
end-stage renal disease (kidney disease), cancers, gestational diabetes, Non-alcoholic 
steatohepatitis (NASH), cardiovascular diseases complications, infectious diseases; (4) 
intervention periods of < 2 months; (5) vitamin D supplementation provided as a single 
dose; and (6) study performed in children and/or adolescents (<18 years). 
Titles and abstracts were screened by two authors (A.P. and M.A.v.B.). Final study 
selection, based on the inclusion criteria, was done by two authors (A.P. and M.A.v.B.) and 
approved by another author (E.E.B.). Any disagreements between the authors were resolved 
through discussion with the fourth author (J.W.E.J.).
Data extraction and management
 Data were extracted by two authors (A.P., M.A.v.B.). Data extracted from each 
study included the following items: first author, reference, year of publication, country of 
study, study design, inclusion criteria, sample size, form of vitamin D, dose and frequency 
of vitamin D supplementation, any co-supplementation (e.g. diet or calcium), treatment 
control group, duration of supplementation, participants’ characteristics [n, sex (% male), 
age, BMI, ethnicities], comorbidities, baseline and follow-up serum 25(OH)D levels and 
outcome measures (e.g. M value or glucose infusion rate (GIR) or insulin-mediated glucose 
uptake derived from clamp, Matsuda index, Insulin sensitivity index, 2h glucose or AUC 
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glucose from an OGTT)] (Table 1). The corresponding author of an eligible publication was 
contacted by e-mail for additional data when relevant. Any further necessary calculations 
on study data, such as converting measurement units or calculating standard deviation (SD), 
was conducted by the first author (A.P.) and checked by another author (M.A.v.B.). Serum 
25(OH)D levels were collated in nmol/L; a multiplication factor of 2.456 was used to convert 
25(OH)D levels from ng/mL to nmol/L. 2-hour glucose tolerance test glucose concentrations 
(2h-glucose) were collated in mmol/L; we used a multiplication factor of 0.0555 to convert 
glucose levels from mg/dL to mmol/L, as appropriate (27). 
Quality assessment
 The quality of selected RCTs was assessed independently by two authors (A.P., 
M.A.v.B.) using the risk of bias checklist (RoB) from the Cochrane Collaboration (28). The 
quality assessments of the checklist included (1) bias from randomization process (random 
sequence generation and allocation concealment), (2) bias due to deviations from intended 
interventions (blinding of participants and personnel), (3) bias due to missing outcome data, 
(4) bias from measurements of the outcome, (5) bias from selection of reported result, and 
other sources of bias. Each criterion could be answered in three ways: “low risk” (adequate 
information), “unclear risk” (if there was unclear information), and “high risk” (if there was 
a high concern). Study quality and the risk of bias in the eligible RCTs was systematically 
assessed using software Review Manager 5.3 (The Nordic Cochrane Centre, The Cochrane 
Collaboration, Copenhagen, Denmark, 2014).
Data synthesis and statistical analysis
 To calculate the effect size of each study, we used the mean change and SD of 
the outcome measures from baseline to the end of the intervention in the control and 
intervention groups (29). When the outcome measure was reported as mean and 95% 
confidence interval [CI] or mean and standard error of mean (SEM), values were estimated 
using Cochrane Review Manager 5.3 software (The Nordic Cochrane Centre, The Cochrane 
Collaboration, Copenhagen, Denmark, 2014) (30). If the outcome measures were reported 
in median, range or 25th–75th percentiles (P25–P75), mean and standard SD values were 
estimated using formulas published by Wan et al (31). If the outcome measures were only 
reported in figures, we used software to estimate the value. SDs of the mean difference 
were estimated using the following formula: SD = square root [(SD pre-treatment)2 + (SD 
post-treatment)2) - (2R * SD pre-treatment * SD post-treatment)]. Because the pretest–
posttest correlation coefficients (r) were not reported in studies, an r value of 0.5 was 
assumed throughout this meta-analysis (30). If a study included more than two intervention 
groups (e.g. two different doses of vitamin D), which were compared with one placebo 
(control) group, the number of subjects of the control group was divided by the number 
comparisons. If the outcome measurement was performed at multiple time-points after the 
intervention period, we only used first time-point after the intervention (29).
 The effect size is reported as standardized mean difference with its 95% confidence 
interval (CI) (26, 32). Standardized mean difference is used as a summary statistic in meta-
analysis when the studies all assess the same outcome but measure it in a variety of ways (in 
this study for example, all studies measured insulin sensitivity but use different methodology 
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i.e. clamp or Matsuda index or insulin sensitivity index). A random-effects model was used 
to estimate outcomes. Heterogeneity was assessed using the I2 (I square) statistic, indicating 
what proportion of the variation in observed effects across studies is due to the variation 
in true effects, with values above 60% indicating substantial heterogeneity. A p-value < 
0.05 is considered statistically significant (29).  The analysis was performed and generated 
using Cochrane Review Manager 5.3 software (The Nordic Cochrane Centre, The Cochrane 
Collaboration, Copenhagen, Denmark, 2014).  The PRISMA checklist was used as a guide for 
checking the quality of our systematic review (Supplemental Table S2).
Publication Bias
 Publication bias was analyzed by visual inspection of the funnel plots.
Meta regression and sensitivity analysis
 If the heterogeneity was >60%, additional analyses were conducted. Meta-
regression analysis and sensitivity analysis using the leave-one-out method (removing one 
study each time and repeating the analysis) were applied to gain insight into the source of 
the heterogeneity (29). 
Results
Study characteristics
 In total, 18 RCTs (33-50) published between 2011 and 2018 with 1220 participants 
were included in the current meta-analysis. Characteristics of the studies are summarized 
in Table 1. The studies were conducted in the United States of America (n=5), Canada (n=1), 
Iran (n=1), India (n=1), Malaysia (n=1), Australia (n=2), The Netherlands (n=1), Denmark 
(n=1), Norway (n=1), Finland (n=1), Sweden (n=1), Austria (n=1), and Italy (n=1). Most stud-
ies included both men and women, except two studies that included only women (43, 45) 
and two other studies that included only men (44, 50). Among the 18 studies, 8 enrolled 
several ethnic populations (multi-ethnicity) (33, 36-38, 40, 46-48), two enrolled individuals 
from African-American ethnicity (34, 44) two enrolled in Asians (43, 45), one enrolled par-
ticipants from Middle-Eastern countries (35), and five studies did not provide information 
about ethnicity (39, 41, 42, 49, 50). Sixteen trials were in participants with overweight, obe-
sity, prediabetes, type 2 diabetes, or metabolic syndrome, two of these trials also included 
apparently healthy participants (40, 50), while participants in the two other trials had PCOS 
(Polycystic Ovary Syndrome) (45) or a history of GDM (Gestational Diabetes Mellitus) (43). 
Studies used different cut-offs for baseline vitamin D levels: nine studies (34, 37-40, 45-47) 
recruited individuals with vitamin D levels <50 nmol/L, and the others (33, 35, 36, 41, 42, 44, 
48-50) included individuals with vitamin D levels <75 nmol/L at the beginning of trial (Table 
1). Mean serum vitamin D 25(OH)D concentrations at baseline varied from 19.2 nmol/L (45) 
to 59.9 nmol/L (33) in vitamin D-supplemented groups and 16.9 nmol/L (45) to 61.4 (33) in 
placebo groups. The mean oral dose of vitamin D was 4,608 IU per day (range 1,200 IU (37) 
to 12,695 IU (36) per day), with the majority of studies providing daily doses ≤ 4000 IU (33, 
34, 37-39, 41, 43, 45, 46, 48-50). The duration of vitamin D supplementation ranged from 2 
(42) to 12 months (44).
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Author (Year)
Study 
location
N
 subjects 
(Tx/Px)
Sex
Ethnicity
BM
I (kg/m
2)
H
ealth status
Vitam
in D levels 
at Baseline 
(nm
ol/L)
Vitam
in D levels 
after intervention 
(nm
ol/L)
Type of vitam
in D; 
m
ode of delivery; 
and dose (IU
/day)
Analytical 
m
easures of 
vitam
in D
Duration 
(m
onth)
O
utcom
e m
easured
M
itri et al. (2011)
U
SA
23/24
M
/F
M
ulti-ethnic
≥ 25 (≥23 if 
Asian)
Prediabetes (IG
T, 
IFG
, H
bA1c≥5.8%
)
T: 59.9±2.7
§
T: +15.7±3.7
§ 
(Change from
 
baseline)
Vitam
in D
3; oral; 
2000
LC-M
S
4
Insulin sensitivity 
index (FIVG
TT), 2h-
glucose (O
G
TT)
P: 60.4±2.7
§
P: –20.5±3.5
§
Harris et al. (2012)
U
SA
43/46
M
/F
African-Am
erican
25-39.9 
Prediabetes or 
early T2D (HbA1c 
6.7-7%
); baseline 
vitam
in D 25(O
H)D 
<50 nm
ol/L
T: 39.6±12.9;
T: 41.6±3.1
§  
(Change from
 
baseline)
Vitam
in D
3; oral; 
4000
RIA
3
M
atsuda index, 2h-
glucose (O
G
TT)
P: 38.2±15.5
P: 0.9±2.9
§
Iraj et al. (2012)
Iran
20/20
M
/F
M
iddle-Eastern
≥ 25
First degree 
relatives of T2D; 
Vitam
in D
 25(O
H)D
 
<75 nm
ol/L; 
Prediabetes
T: 27.5±15.0 
T: 87.4±49.9 
Vitam
in D
3; 
injection; 10000
CLIA
2
M
atsuda index, AU
C 
G
lucose (O
G
TT) 
P: 28.2±15.0
P: 38.7±54.9
Davidson M
B et al. 
(2013)
U
SA
56/53
M
/F
M
ulti-ethnic 
(Hispanic and 
African-Am
erican)
≥ 25
Prediabetes; 
Vitam
in D
 25(O
H)D
 
<75 nm
ol/L
T: 54.9±12.5 
T: 169.6±37.4 
Vitam
in D
3; oral; 
12695
LC-M
S
3
M
atsuda index, 2h-
glucose
P: 54.9±12.5
P: 54.9±17.4
O
osterw
erff et al. 
(2014)
N
etherlands
53/57
M
/F
M
ulti-ethnic 
(M
oroccan, 
Surinam
e, Turkey)
≥ 25
IFG
 or IG
T; Vitam
in 
D 25(O
H)D <50 
nm
ol/L
T: 25.0±10.8
T: 60.0±16.0
Vitam
in D
3; oral; 
1200
LC-M
S
4
Insulin sensitivity 
index, 2h-glucose
P: 22.0±11.0
P: 23.0±15.0
G
agnon et al. 
(2014)
Australia
35/45
M
/F
M
ulti-ethnic
25-40 
Vitam
in D
 25(O
H)D
 
<50 nm
ol/L, 
Prediabetes
T: 47.0±13.0 
T: 89.1±16.5 
Vitam
in D
3; oral; 
2000
CLIA
6
M
atsuda index
P: 43.2±13.0
P: 41.4±16.3
Table 1. Characteristics of random
ized-controlled trial studies included in the m
eta analysis (continued)
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Author (Year)
Study 
l ocation
N
 subjects 
( Tx/Px)
Sex
Ethnicity
BM
I (kg/m
2)
H
ealth status
Vitam
in D
 levels at Baseline 
( nm
ol/L)
Vitam
in D
 levels after 
i ntervention (nm
ol/L)
Type of vitam
in D
; 
m
ode of delivery; 
a nd dose (IU
/day)
Analytical 
m
easures of 
v itam
in D
D
uration 
( m
onth)
O
utcom
e m
easured
Kam
pm
ann et al. (2014)
D
enm
ark
08-Jul
M
/F
N
R
≥ 25
T2D
; Vitam
in D
 
25(O
H
)D
 <50 
nm
ol/L
 §
0.
91
±9
.4
01
 :
T
 §
9.
4±
0.
13
 :
T
Vitam
in D
3; oral; 
6400
ELISA
3
M
-value derived from
 clam
p
§8
.3
±1
.2
3 :
P
§8
.3
±8
.4
3 :
P
M
itchell et al. (2015)
U
SA
40/50
M
/F
M
ulti-ethnic
M
edian 25 
Vitam
in D
 25(O
H
)D
 
<50 nm
ol/L
 9
.9
2±
3.
70
1 :
T
 5
.7
1±
9.
44
 :
T
Vitam
in D
2; oral; 
7142
LC-M
S
3
Insulin sensitivity index (FIVG
TT)
9.
42
±9
.9
4 :
P
5.
71
±9
.4
4 :
P
Tuom
ainen et al. (2015)
Finland
24/21/21
M
/F
N
R
≥ 25
Prediabetes; 
Vitam
in D
 25(O
H
)D
 
<75 nm
ol/L
M
ean T+P baseline: 57.0 ± 11.0
T1: +27.7±17.2 (Change fro m
 
baseline)
T1 Vitam
in D
3; 
oral; 1600
H
PLC-CEA
D
5
M
atsuda index
T2: +45.0±23.4 (Change from
 
baseline)
T2 Vitam
in D
3; 
oral; 3200
H
PLC-CEA
D
5
M
atsuda index
P: +4.1±17.3
W
agner et al. (2016)
Sw
eden
21/22
M
/F
N
R
≤ 32
Prediabetes or drug-
naive diabetes; 
H
bA
1c ≤ 7.9%
; FPG
 
<9 m
m
ol/L; Vitam
in 
D
 25(O
H
)D
 <75 
nm
ol/L
M
edian (IQ
R) T:  43.0 (36.0–50.0); 
M
edian change (IQ
R) T:  +42.0 
(32.0–50.0)
Vitam
in D
3; oral; 
4285
CLIA
2
G
IR derived from
 clam
p
P:  43.0(37.0–54.0)
P:  0.0(-7.0–11.0)
Yeow
 et al. (2015)
M
alaysia
13/13
F
A
sian
23 - 31
H
istory of G
D
M
 
during last 
pregnancy6-48 
m
onths 
postpartum
; 
hypovitam
inosis 
(Vitam
in D
 25(O
H
)D
 
15-50 nm
ol/L)
M
edian (IQ
R) T:  35.6 (25.6-43.9) 
M
edian change (IQ
R) T:  +51.1 
(39.9- 76.1)
Vitam
in D
3; oral; 
4000
ECLIA
6
Insulin sensitivity index, 2h-glucose
P:  35.1 (21.6- 40.7)
P:  –0.2 (-10.18–11.8)
Barengolts et al. (2015)
U
SA
87/86
M
A
frican-A
m
erican
28-39
Fasting glucose 5.3-
6.9 m
m
ol/L; H
bA
1c 
5.7-6.4%
; Vitam
in D
 
25(O
H
)D
 12.5-75 
nm
ol/L
 9
.5
4±
1.
02
1 :
T
7.
11
±7
.6
3 :
T
Vitam
in D
2; oral; 
7142
CLIA
12
M
atsuda index
Table 1. Characteristics of random
ized-controlled trial studies included in the m
eta analysis (continued)
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Author (Year)
Study location
N
 subjects 
(Tx/Px)
Sex
Ethnicity
B
M
I (kg/m
2)
H
ealth status
Vitam
in D
 levels at 
B
aseline (nm
ol/L)
Vitam
in D
 levels 
after intervention 
(nm
ol/L)
Type of vitam
in D
; 
m
ode of delivery; 
and dose (IU
/day)
Analytical 
m
easures of 
vitam
in D
D
uration 
(m
onth)
O
utcom
e m
easured
G
arg et al. 
(2015)
India
15/17
F
Asian
≥ 23
PC
O
S, vitam
in D
 25(O
H
)D
 
<50 nm
ol/L
T: 19.2±15.1 
T: 78.6±34.6 
Vitam
in D
3; oral; 
4000
C
LIA
6
M
atsuda index, AU
C
 
G
lucose
P: 16.9±6.1
P: 16.7±5.8
M
ousa et al. 
(2017)
Australia
28/26
M
/F
M
ulti-ethnic
≥ 25
Vitam
in D
  25(O
H
)D
 <50 
nm
ol/L
T: 31.4±12.6 
T: 88.4±21.0 
Vitam
in D
3; oral; 
4000
C
LIA
4
M
-value derived from
 
clam
p
P: 34.2±10.0
P: 36.1±15.3
G
ulseth et al. 
(2017)
N
orw
ay
33/29
M
/F
M
ulti-ethnic 
(N
ordic and 
South-Asians)
< 45
Type 2 diabetes; Vitam
in D
 
25(O
H
)D
 <50 nm
ol/L
T: 38.0±11.9 
T: 53.7±9.2 
Vitam
in D
3; injection 
& oral; 3333
R
IA
6
G
IR
 derived from
 clam
p
P: 36.8±12.6
P: 38.2±12.9
Lerchbaum
 et al. 
(2017)
Austria
49/49
M
N
R
M
edian 25
Vitam
in D
 25(O
H
)D
 <75 
nm
ol/L
M
edian (IQ
R
) T: 52.0 
(42.0 – 65.0) 
M
edian (IQ
R
) T: 107.0 
(89.0 – 119.0) 
Vitam
in D
3; oral; 
2857
LC
-M
S
3
M
atsuda index, AU
C
 
G
lucose
P: 51.0 (43.0 – 68.0)
P: 69.0 (46.0 – 79.0)
M
oreira-Lucas et 
al. (2017)
C
anada
36/35
M
/F
M
ulti-ethnic
< 40
Vitam
in D
 25(O
H
)D
 ≤ 65 
nm
ol/L and H
bA1c of 5.4%
 
to 6.4%
T: 48.1±14.3 
M
ean change 
(95%
C
I) T: 50.6 (36.7, 
64.6) 
Vitam
in D
3; oral; 
4000
LC
-M
S
6
M
atsuda index, AU
C
 
G
lucose
P: 47.6±14.3
P: -2.11 (-6.11, 1.89)
C
efalo et al. 
(2018)
Italia
44083
M
/F
N
R
> 25
BM
I≥30 kg/m
2; Vitam
in 
25(O
H
)D
 <75 nm
ol/L
T: 36.7±13.2 
T: 74.8±18.7 
Vitam
in D
3; oral; 
3571
N
R
3
Insulin m
ediated glucose 
uptake, AU
C
 G
lucose 
(from
 O
G
TT)
P: 34.7±21.1
P: 41.7±7.7
Table 1. Characteristics of random
ized-controlled trial studies included in the m
eta analysis
Abbreviations: 25(O
H)D, 25-hydroxyvitam
in D; AU
C, Area U
nder Curve; BM
I, body m
ass index; CLIA, chem
ilum
inescence im
m
unoassay; ECLIA, electro-chem
ilum
inescence im
m
unoassay; FPG, 
Fasting Plasm
a Glucose; GIR, Glucose Infusion Rate; HbA1c, Glycated haem
oglobin; IFG, Im
paired Fasting Glucose; IGT, Im
paired Glucose Tolerance; LC-M
S, Liquid Chrom
atography-M
ass Spectro-
photom
etry; M
, M
ale; F, Fem
ale; N
R, N
ot Reported; RIA, Radioim
m
unoassay; Tx/Px, Treatm
ent/Placebo group; T, Treatm
ent; P, Placebo. §m
ean±SE
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The effect of vitamin D supplementation on insulin sensitivity 
 There were 18 studies with sufficient data to be included in the meta-analysis 
to estimate the overall effect of vitamin D supplementation on insulin sensitivity derived 
from a clamp (39, 42, 46, 47, 49) or indices of insulin sensitivity derived from an oral or 
intravenous glucose tolerance test (33-38, 40, 41, 43-45, 48, 50). The total number of 
included individuals was 1220; of these, 612 received vitamin D supplementation, and 
608 patients received placebo. From the 13 studies that used the Matsuda index derived 
from OGTT and/or insulin sensitivity index from IVGTT (33-38, 40, 41, 43-45, 48, 50), none 
reported a significant change (increase or decrease) in insulin sensitivity after vitamin D 
supplementation compared with placebo. Furthermore, among those five studies in which 
the outcome of insulin sensitivity was derived from a clamp (39, 42, 46, 47, 49), only one 
study (Cefalo et al (49)) reported a statistically significant improvement of insulin sensitivity. 
Figure 2. Forest plot of the effect of vitamin D supplementation on insulin sensitivity. Horizontal lines span 
individual study 95% confidence intervals (CI). Diamonds represent the combined study standardized mean value 
and the corresponding 95% CI values.
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 Based on a random-effect meta-analysis, comparing the standardized mean 
difference of the change in insulin sensitivity from baseline between the vitamin D–
supplemented and placebo groups, the overall effect on insulin sensitivity was not significant 
after vitamin D supplementation (standardized mean difference: -0.01, 95% CI: -0.12 to 0.10, 
P= 0.87; I2= 0%, P=0.60) (Figure 2).  
The effect of vitamin D supplementation on postprandial glucose concentrations
 There were 12 studies that reported 2h-glucose concentrations (6 studies) (33, 34, 
36, 41-43) or AUC Glucose (6 studies) (35, 37, 45, 48-50) as an outcome measure. A meta-
analysis of these data including 745 individuals (n = 379 treated with vitamin D and n = 
366 with placebo) was performed to compare the mean change in 2h-glucose and/or AUC 
Glucose between the beginning and the end of study. Vitamin D supplementation had no 
effect on post-prandial glucose with a standardized mean difference of 0.09 (95% CI: -0.08 
to 0.25, P = 0.29; I2 = 18%, P=0.26) (Figure 3A).
(3A)
Figure 3A. Forest plots of the effect of vitamin D supplementation on postprandial glucose, Horizontal lines span 
individual study 95% confidence intervals (CI). Diamonds represent the combined study standardized mean value 
and the corresponding 95% CI values.
The effect of vitamin D supplementation on serum vitamin D levels
 All eighteen trials (n = 1223; 613 individuals treated with vitamin D and 
610 individuals with placebo) reported the change in serum vitamin D level after the 
intervention. There was a significant increase in the serum vitamin D level in the vitamin D 
supplementation groups compared with the control groups (standardized mean difference 
= 2.25; 95%CI: 1.90–2.60, p < 0.001) (Figure 3B) with considerable heterogeneity (I2 = 81%; 
p<0.001).
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(3B)
Figure 3B. Forest plots of the effect of vitamin D supplementation on serum vitamin D levels, Horizontal lines span 
individual study 95% confidence intervals (CI). Diamonds represent the combined study standardized mean value 
and the corresponding 95% CI values.
Risk of bias 
 Most included studies had a low risk of bias according to randomization process 
(random sequence generation and allocation concealment), blinding participants 
(comparability of intervention groups and placebo (control) groups), incomplete outcome 
data (clear description of dropout/withdrawal/attrition rate). The blinding of outcome 
assessment was not clearly mentioned in some of studies (34-36, 41, 44, 45, 48, 49), resulted 
in unclear risk of detection bias. The overall quality assessment of the included trials in this 
meta-analysis is shown in Supplemental figures S1A-B.
Publication bias
 The visual inspection of funnel plots of changes in insulin sensitivity, postprandial 
glucose and serum vitamin D changes in this meta-analysis following vitamin D 
supplementation did not indicate publication bias (Supplemental figures S2A-C).
Meta regression and sensitivity analysis
 Regarding the change in serum vitamin D levels following supplementation, there 
was a considerable heterogeneity (I2=81%). A meta-regression analysis of dose or duration 
with standardized mean difference of serum vitamin D levels showed that the dose of vitamin 
D supplementation may partly explain the heterogeneity (Supplemental Table S3). Further 
sensitivity analysis by leave-one-out analysis, shows that no single study is responsible for 
the heterogeneity of changes in serum vitamin D levels. 
Discussion
 We conducted a systematic review and meta-analysis of 18 RCTs to determine the 
effect of vitamin D supplementation on insulin sensitivity in individuals with or at risk of 
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insulin resistance. In this meta-analysis, vitamin D supplementation had no significant effect 
on insulin sensitivity derived from a hyperinsulinemic euglycemic clamp or the Matsuda 
Index derived from an OGTT and/or Insulin sensitivity index from IVGTT. Additionally, no 
significant changes in 2h glucose or AUC glucose during an OGTT were observed following 
vitamin D supplementation. 
 In our analysis, study populations were often characterized by the presence of 
overweight or obesity (33-39, 41-44, 46-49), accompanied with baseline serum concentrations 
of 25(OH)D <50 nmol/L (33-44, 46-50) or <75 mmol (35, 36, 41, 42, 44, 49, 50). Indeed, it has 
been described that human obesity often coincides with low circulating vitamin D 25(OH)
D levels (5). Several mechanisms, such as uptake/sequestration of vitamin D within adipose 
tissue (51) and volumetric dilution due to increased body volume (52) may explain the link 
between obesity and low vitamin D levels. Furthermore, a comprehensive systematic review 
by Autier and colleagues suggests that the low serum vitamin D levels could also be due to 
the chronic low grade inflammation which is an important characteristic of individuals with 
obesity and T2D (53). Thus, vitamin D supplementation in human overweight/obesity could 
be expected to increase serum vitamin D 25(OH)D levels. In this meta-analysis we showed 
that vitamin D supplementation increased the mean vitamin D 25(OH)D level of treatment 
group in all studies, although with considerable heterogeneity. Additional meta-regression 
analysis showed that some of the heterogeneity is explained by dose, but not by treatment 
duration. Nevertheless, in our meta-analysis, improving vitamin D 25(OH)D concentrations 
did not translate into an improvement in insulin sensitivity and glucose metabolism. In the 
present meta-analysis, we included only studies using standardized methodologies (non 
fasting measures of insulin sensitivity), either by multi-sampled OGTTs or IVGTTs (33-38, 40, 
41, 43-45, 48, 50) or the gold standard hyperinsulinemic euglycemic clamp (39, 42, 46, 47, 
49). Our meta-analysis, which shows no effect of vitamin D supplementation on peripheral 
insulin sensitivity and postprandial glucose handling, supports several other findings which 
used fasting indices of insulin sensitivity (e.g. HOMA-IR) (18, 19). 
 It has been shown that postprandial glycaemia is strongly associated with obesity 
(3), and predicts cardiovascular events among insulin resistant individuals (4, 54). Wood 
et al. (55) and Manson et al. (56). have shown that vitamin D supplementation did not 
result in the prevention of cardiovascular events. The most recent work by Pittas et al. (57) 
showed that vitamin D supplementation (4000 IU) did not result in a significantly lower risk 
of diabetes, assessed by 2h OGTT in 2423 individuals. The skeletal muscle is a key organ for 
peripheral insulin sensitivity as it is responsible for the majority of glucose disposal during 
postprandial conditions (24, 58). Although effects of vitamin D on glucose responsiveness, 
insulin receptor substrate (59) and insulin sensitivity (17), muscle mitochondria biogenesis 
(16) as well as lipid metabolism (17) have been documented at the transcriptional and 
post-translational level in vitro, our analysis shows no effect on postprandial glucose 
concentrations suggests that these beneficial effects do not translate into beneficial effects 
at the functional level. Studies have shown that vitamin D may affect insulin secretion (15, 
33) rather than insulin sensitivity per se. Vitamin D may contribute to normalization of 
extracellular calcium, ensuring normal calcium flux through cell membranes and regulate 
the beta-cell calcium pool (15). Nevertheless, whether there is sufficient evidence that 
vitamin D supplementation may improve insulin secretion in postprandial condition (e.g. 
disposition index) needs further investigation. Furthermore, there is only one trial included 
in this meta analysis, by Cefalo et al. (49), which reported a significant increase of insulin 
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sensitivity derived from a clamp after vitamin D supplementation. Of note, in that study 
vitamin D supplementation was combined with a low-calorie diet intervention, yet the 
sample size of this study was relatively small. Therefore, whether combining vitamin D 
supplementation with diet restriction may improve insulin sensitivity in humans with or at 
risk of insulin resistance needs further investigation in a well-controlled study.
 When interpreting the results, several factors should be taken into consideration. 
The optimal time of intervention and dose that are necessary to evaluate the effects of 
vitamin D supplementation on parameters related to glucose metabolism and insulin insulin 
sensitivity is not well established. We showed that neither dose nor treatment duration 
were associated with changes in insulin sensitivity and postprandial glucose. It also should 
be noted that the results could be affected by other factors such variation in age, season (19) 
and ethnicity (23) as well as tissue-specific metabolism and insulin resistance (60). A recent 
meta-analysis in type 2 diabetes populations by Li et al. (23) has suggested that vitamin 
D supplementation may have more beneficial effects in individuals from Middle eastern 
ethnicity as compared to other ethnicities, but some of the included studies on which this 
suggestion was based were of questionable quality. In this meta-analysis, we could not 
perform subgroup analysis based on ethnicity because 8 out of 18 trials (33, 36-38, 40, 46-
48) were conducted in multi-ethnic populations, whereas 5 other studies (39, 41, 42, 49, 
50) did not report any information about ethnicity. In addition, the heterogeneity regarding 
the change in serum vitamin D levels may also be partly explained by compliance that was 
achieved during intervention, which we were unable to ascertain in more detail. Another 
limitation might be that the number of individuals who participated in the included studies 
was relatively small possibly due to the invasive and expensive character of the measurement 
(e.g. clamp). Despite the fact that the number of studies using clamps, the gold standard for 
the measurement of insulin sensitivity, was relatively small (only 5 studies), the outcome 
on insulin sensitivity derived from clamps was similar to the outcome based on the results 
from OGTTs and IVGTTs (13 studies). In addition, 3 studies that met our inclusion criteria and 
used a clamp (61-63) were published in 2019, after the window for being included in the 
meta analysis. After repeating the meta-analysis with in total 21 studies (3 studies in 2019 
and the original 18 studies), the outcome did not change (Supplemental figures S3A-C). In 
conclusion, this systematic review provides no evidence that supplementation with vitamin 
D has a beneficial effect on peripheral insulin sensitivity, as determined by hyperinsulinemic 
euglycemic clamp, the Matsuda or insulin sensitivity index, and postprandial glucose 
concentrations after an OGTT in people with, or at risk for insulin resistance.
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Supplemental Table S1. The search terms for each database
No Database Search terms
1 PubMed
("overweight"[MeSH Terms] OR "overweight"[All Fields]) OR ("obesity"[MeSH 
Terms] OR "obesity"[All Fields]) OR Obes[All Fields] OR "prediabetic state"[MeSH 
Terms] OR ("prediabetic"[All Fields] AND "state"[All Fields]) OR "prediabetic 
state"[All Fields] OR "prediabetes"[All Fields] OR ("diabetes mellitus, type 
2"[MeSH Terms] OR "type 2 diabetes mellitus"[All Fields] OR "diabetes mellitus, 
type 2"[All Fields]) OR ("insulin resistance"[MeSH Terms] OR ("insulin"[All Fields] 
AND "resistance"[All Fields]) OR "insulin resistance"[All Fields]) OR ("insulin 
resistance"[MeSH Terms] OR ("insulin"[All Fields] AND "resistance"[All Fields]) 
OR "insulin resistance"[All Fields] OR ("insulin"[All Fields] AND "sensitivity"[All 
Fields]) OR "insulin sensitivity"[All Fields]) OR ("blood glucose"[MeSH Terms] OR 
("plasma blood"[All Fields] AND "glucose"[All Fields]) OR "blood glucose"[All Fields] 
OR ("glucose"[All Fields] AND "blood"[All Fields]) OR "glucose, blood"[All Fields]) 
AND ("vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR "cholecalciferol"[All 
Fields]) AND (Randomized Controlled Trial[ptyp] AND "humans"[MeSH Terms])
2 Cochrane
(overweight OR obesity OR obese OR prediabetes OR type 2 diabetes mellitus) 
AND (vitamin D OR vitamin D3 OR vitamin D2) AND (insulin sensitivity OR insulin 
resistance) AND (glucose control OR blood glucose)
3 Embase
(blood glucose, insulin resistance, insulin sensitivity, non insulin dependent diabetes 
mellitus, obesity, prediabetes, supplementation, vitamin d, cholecalciferol) 
using a combination of multi-field search in all fields and EMTREE
4 Web of Science
(overweight OR obesity OR prediabetes OR type 2 diabetes mellitus) AND (vitamin 
D OR vitamin D3 OR vitamin D2) AND (insulin sensitivity OR insulin resistance) AND 
(plasma glucose OR OGTT)
5 CINAHL
(overweight OR obesity OR obese OR prediabetes OR type 2 diabetes mellitus) AND 
(vitamin D OR 25 hydroxyvitamin D OR vitamin D3 OR vitamin D2) AND (insulin 
sensitivity OR insulin resistance) AND (blood glucose OR glucose control)
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Supplemental Table S2. The PRISMA (2009) Checklist 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal. 
pmed1000097. For more information, visit: www.prisma-statement.org
Section/topic # Checklist item 
Reported 
on page # 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1
Structured summary 2
Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number. 
2
Rationale 3 Describe the rationale for the review in the context of what is already known. 3
Objectives 4
Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS). 
4
Protocol and 
registration 
5
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number. 
4
Eligibility criteria 6
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale. 
5
Information sources 7
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched. 
5
Search 8
Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated. 
5,6
Study selection 9
State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis). 
7
Data collection 
process 
10
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators. 
7,8
Data items 11
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made. 
7,8
Risk of bias in 
individual studies 
12
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done 
at the study or outcome level), and how this information is to be used in any data synthesis. 
8
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 8,9
Synthesis of results 14
Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis. 
9
Section/topic # Checklist item 
Reported 
on page # 
Risk of bias across 
studies 
15
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies). 
9
Additional analyses 16
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified. 
9
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram. 
9 (and 
Figure 1)
Study characteristics 18
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations. 
9 to 11
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 12
Results of individual 
studies 
20
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
10,11
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. 10,11
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see Item 15). 12
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). 12
Summary of 
evidence 
24
Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers). 
12 to 14
Limitations 25
Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias). 
15
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 15
Funding 27
Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review. 
16
FUNDING 
TITLE 
ABSTRACT 
INTRODUCTION 
METHODS 
RESULTS 
DISCUSSION 
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Supplemental figures S1A-B. Risk of bias analysis (A) The analysis of the individual studies included in the systematic 
review and meta-analysis. Green dot = low risk of bias; yellow dot = unclear risk of bias; red dot = high risk of bias 
(B) The summary of the risk of bias analysis.
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(A)
(B)
(C)
Supplemental fi gures S2A-C. Funnel plot of RCTs the eff ect of vitamin D supplementati on on (A) insulin sensiti vity; 
(B) postprandial glucose; (C) serum vitamin D levels. Symmetrical funnel plots suggest publicati on bias is unlikely. 
RCTs, randomized controlled trials; SE(SMD) Standard Error of Standardized Mean Diff erence.
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Supplemental figures S3A-C. Forest plots and funnel plots after repeating the meta-analysis with in total 21 stud-
ies (additional 3 studies in 2019 and the original 18 studies) of the effect of vitamin D on: (S3A) insulin sensitivity; 
(S3B) postprandial glucose; (S3C) serum vitamin D levels. 
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General Discussion
 The increasing prevalence of obesity substantially leads to an increased risk for 
the development of insulin resistance, type 2 diabetes mellitus, cardiovascular diseases 
(hypertension and stroke), and certain types of cancer. In addition, obesity and obesity-
associated health complications might contribute to a reduced quality of life (1). Obesity 
is often characterized by low vitamin D 25(OH)D3 concentrations (also known as vitamin D 
deficiency or hypovitaminosis D) as indicated by a recent population-based study reporting 
42.5% vitamin D deficiency among individuals with BMI ≥ 30 kg/m2 (2). The underlying 
mechanism linking vitamin D 25(OH)D3 and obesity is still unclear (3), whereas reports 
on the link between vitamin 1,25(OH)2D3 concentrations and obesity are inconsistent (4, 
5). Additionally, in the past decades, insulin resistance and type 2 diabetes mellitus (T2D) 
have been linked with vitamin D deficiency (6). The US National Health Survey (NHNES) 
2001-2006 showed that obese individuals with vitamin D deficiency had higher risk for the 
development and maintenance of insulin resistance as compared to obese individuals with 
sufficient vitamin D levels (7).
Therefore, in the present thesis we investigated whether and how vitamin D is related 
to insulin sensitivity in human obesity. At first, we investigated whether uptake and release 
of vitamin D by abdominal SAT is impaired in obese individuals and may thereby possibly 
contribute to the reduced circulating vitamin D levels in vivo in human obesity (chapter 
3). Next, we aimed to gather (mechanistic) insight into the association between circulating 
vitamin D metabolites [25(OH)D3 and 1.25(OH)2D3] and gene-expression of vitamin 
D-related metabolism within SAT and tissue-specific insulin sensitivity in overweight/obese 
humans (chapter 4). Furthermore, we examined whether genetic variation in the vitamin 
D receptor is related to tissue-specific insulin sensitivity in overweight/obesity individuals 
in the large Pan-European dietary intervention trial (DiOGenes) (chapter 5). Finally, we 
conducted a meta-analysis of human randomized controlled-trials to investigate whether 
there is sufficient evidence that vitamin D may affect insulin sensitivity derived from the 
gold standard hyperinsulinemic euglycemic clamp or from the Matsuda or insulin sensitivity 
indices derived from OGTT or IVGTT respectively (chapter 6). 
Association of circulating vitamin D, obesity and insulin resistance 
 
 The prevalence of low circulating vitamin D 25(OH)D3 levels (<50 nmol/L) has been 
reported to be about 40.7% in individuals with obesity and insulin resistance (2). In line with 
these data, about 45.7% of obese-insulin resistant individuals in our study (chapter 4) were 
classified as vitamin D deficient. The above data suggest that vitamin D 25(OH)D3 deficiency 
is a commonly observed characteristic in obese insulin resistant individuals. However, it is 
unclear whether vitamin D deficiency is associated with obesity (BMI) or insulin resistance 
per se.  
 In chapter 4, we conducted a cross sectional analysis in overweight and obese 
individuals with either normal or impaired glucose metabolism to investigate whether 
obesity (BMI) is related to plasma vitamin D metabolites [25(OH)D3 and 1.25(OH)2D3 or 
the ratio between both in overweight/obese individuals. We demonstrated that BMI was 
negatively associated with circulating vitamin D 25(OH)D3 but not with the active metabolite 
of vitamin D [1.25(OH)2D3]. The association between BMI and vitamin D 25(OH)D3 remained 
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significant after adjustment for age and sex. This finding is consistent with other findings, 
indicating an inverse correlation between plasma 25(OH)D3 concentration and BMI across 
age, different ethnicities and in a range of geographic locations (8-11). 
 In contrast to our findings, a previous study in individuals with a wide range of BMI 
(mean±SD= 32.0 ± 6.8; estimated range from 18.4 to 45.6 kg/m2) (12) and  a recent study in 
middle-aged sedentary adults demonstrated a negative correlation between BMI and active 
metabolite of vitamin D [1.25(OH)2D3] independent of age and sex (5). These discrepancies 
could possibly be explained by the different BMI ranges of these studies (i.e., our cohort 
mean±SD= 30.6±2.9; range 25.5 − 38.6 kg/m2 vs. The FIT-AGEING study (5) mean±SD= 
26.7±3.8; estimated range 19.1 − 34.3  kg/m2). 
 In chapter 4, we extended our cross sectional analysis, to determine whether vitamin 
D metabolites relate to tissue-specific insulin sensitivity and whether these relationships are 
independent of BMI, age, and sex. We observed that none of vitamin D metabolites [25(OH)
D3 nor 1,25(OH)D3 nor its ratio] were associated with hepatic, muscle nor adipose tissue 
insulin sensitivity derived from the gold standard two-steps hyperinsulinemic euglycemic 
clamp technique. Further correction for BMI did not change the outcome. In line, Ter Horst 
et al (4), also observed no association between vitamin D 25(OH)D3 and insulin sensitivity 
determined by a gold standard two-steps hyperinsulinemic euglycemic clamp in human 
obesity. 
 As mentioned above there is a large amount of observational studies that 
investigated the link between vitamin D deficiency and insulin resistance, but the outcomes 
are inconsistent (chapter 2). Analyses of the National Health and Nutrition Examination 
Survey 1989–1994 (NHANES III) disclosed that serum 25(OH)D3 was inversely associated 
with diabetes risk and measures of insulin resistance in general population (13). Further 
cross-sectional analysis from population-based study (NHANES 2001-2006), has shown 
that the interaction between low serum 25(OH)D3 and high BMI may explain 47% of insulin 
resistance cases as assessed by HOMA-IR (7). Significant associations have been reported 
between circulating 25(OH)D3 and hyperglycemic clamp-induced insulin response in normal 
glucose tolerant (obese/overweight) individuals of various ethnic backgrounds (14). In 
contrast, a study conducted in a European populations with metabolic syndrome, showed 
that serum vitamin D 25(OH)D3 levels were not associated with insulin action and glucose 
metabolism derived by intravenous glucose tolerance test (IVGTT) after correction for BMI 
(15). In addition, other recent studies have shown no association between vitamin D 25(OH)
D3 and HOMA-IR and Matsuda index after adjustment for BMI (15-18). 
 Of note, vitamin D 25(OH)D3 still needs to be hydroxylated to produce its hormonally 
active metabolite 1,25(OH)2D3 (19). Mechanistically, vitamin D 1,25(OH)2D3 may directly 
affect insulin signaling (20) and/or glucose stimulated pancreatic insulin secretion (21). 
However, as mentioned above, We observed no association between 1,25(OH)D3 markers 
of tissue insulin sensitivity in chapter 4. In contrast, a recent observational study suggested 
1,25(OH)2D3 is independent of age, sex, and BMI for features of metabolic syndrome (MetS) 
(22). However, data on the association of 1,25(OH)2D3 and metabolic markers is limited, 
possibly due to technical issues and vitamin D 1,25(OH)2D3 stability over longer period of 
time (23, 24).  
 Taken together, the majority data suggests that vitamin D 25(OH)D3 deficiency is 
merely associated with BMI but not with indices of insulin resistance. Notably, studies using 
hyperinsulinemic euglycemic clamps, IVGTT as well as the Matsuda index do not report 
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an association between vitamin D 25(OH)D3 deficiency and insulin resistance in line with 
our data in chapter 4. Nevertheless, whether vitamin D deficiency is associated with insulin 
sensitivity in subgroups based on ethnicity, sex and metabolic health status needs to be 
studied further. Data on the association between1,25(OH)2D3, BMI and insulin resistance is 
still inconsistent and warrant further investigation.
Adipose tissue mass and metabolism in relation to vitamin D deficiency 
(inactive and active metabolite)
 As reviewed in the chapter 2, an altered vitamin D metabolism within adipose 
tissue (25) and an increased sequestration of vitamin D in adipose tissue (26) may partly 
explained vitamin D deficiency in obesity. Furthermore, the dilution of vitamin D 25(OH)D3 
due to a higher volume of distribution in obese individuals has been proposed as underlying 
mechanism for low serum 25(OH)D3 concentrations in obesity (27).
 In chapter 2, we described that there is evidence showing that vitamin D-related 
metabolism is altered in obese SAT (25). Wamberg et al. observed a decreased RNA 
expression of 25-hydroxylase enzymes in SAT of obese compared with lean women (25). 
Interestingly, a recent study using the murine 3T3-L1 adipocyte model demonstrated that 
adipocytes are capable of converting vitamin D3 precursor into vitamin D 25(OH)D3, but 
this conversion occurs to a lesser extent in insulin resistant adipocytes due to a reduced 
expression of the 25-hydroxylation enzyme (28). Together, these data may suggest that large 
quantities of vitamin D3 are stored as the native compound, presumably in body fat, and are 
only slowly released as vitamin D 25(OH)D3 due to less efficient 25-hydroxylation in SAT in 
the obese insulin resistant state (29).
 However, in chapter 4, further analysis revealed that the association between BMI 
and plasma vitamin D 25(OH)D3 levels in overweight and obese individuals did not change 
after adjustment for the SAT gene expression of the 25-hydroxylases CYP2J2, CYP27A1; and 
the 1-alpha-hydroxylase enzyme CYP27B1. Our study also did not find any associations 
between vitamin D 1.25(OH)2D3 levels and the expression of 25- or 1-alpha-hydroxylase 
enzymes within SAT. Thus, our results may suggest that BMI and adiposity and not an altered 
adipose tissue metabolism is the main determinant for circulating vitamin D 25(OH)D3 and D 
1.25(OH)2D3 levels in overweight/obese individuals. However, we cannot exclude that other 
hydroxylase enzymes might be involved in vitamins D metabolism in human SAT, which 
needs to be investigated in more detail in future research. 
 Of note, in chapter 4 we only investigated expression of vitamin D enzymes in the 
abdominal SAT. A study in obese women showed that the expression of the  25-hydroxylation 
enzymes (CYP27A1, CYP27B1) was higher in VAT compared to SAT and positively correlated 
with circulating vitamin D 25(OH)D3 concentration (25). Therefore, whether vitamin D 
25(OH)D3 hydroxylation may be regulated differently depending on AT depot as well as the 
relative contribution of AT vitamin D precursor (stored as native compound) to circulating 
25(OH)D3 concentration in obese-insulin resistant state needs further investigation. 
 It was two decades ago, that Wortsman et al documented that vitamin D3 (a 
precursor for inactive vitamin D metabolite/25(OH)D3) is sequestered in adipose tissue of 
obese individuals (26). Furthermore, not only the precursor vitamin D3 (30) but also the 
metabolite vitamin D 25(OH)D3 has been shown to accumulate in abdominal SAT (31). Of 
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interest, an impaired release of vitamin D3 (pre-vitamin D) and vitamin D 25(OH)D3  has been 
documented from subcutaneous adipocytes of obese donor compared lean ex vivo (28). 
This impairment of vitamin D release was co-existing with an impaired lipolytic response 
following beta-adrenergic stimulation in adipocytes from obese donors (28). 
 To investigate the contribution of vitamin D metabolites from abdominal adipose 
tissue, we measured vitamin D metabolites using arterio-venous blood sampling across 
abdominal SAT in combination with AT blood flow measurements in chapter 3. We did 
not observe significant in vivo vitamin D 25(OH)D3 release across SAT of lean or obese 
men following an overnight fast and during acute ß-adrenergic stimulation. However, we 
observed a blunted release of active vitamin D metabolite 1.25(OH)2D3 following ß-adrenergic 
stimulation in obese but not in lean men. Of interest, 1,25(OH)2D3 is a ligand for vitamin D 
receptor (VDR), and it has been shown that VDR expression is increased in abdominal SAT 
of individuals with obesity (32). In line, our data (chapter 4) showed a positive association 
between BMI and VDR expression in abdominal SAT.  Taken together, it could be speculated 
that vitamin D 1,25(OH)2D3 binds to a higher extent to VDR within SAT in individuals with 
obesity, resulting in less spillover/release of vitamin D 1,25(OH)2D3 in the circulation in obese 
but not in lean individuals, which still needs further investigation.
 The exact association between the impaired ß-adrenergic stimulated lipolysis 
and vitamin D release and to what extent they are interconnected remains to be largely 
determined. Among the physiological factors stimulating release of free fatty acids (FFAs) 
from adipose tissue, exercise contributes to the greatest proportion (33).  During exercise, 
lipolytic hormones  (such as catecholamines and atrial natriuretic peptide (ANP)) (34, 35) and 
ATBF are increased (36). Several cross-sectional studies report a positive correlation between 
serum 25(OH)D3 concentrations and higher physical activity independent of BMI (37, 38). 
Interestingly, a recent RCT (39) has observed an elevated serum 25(OH)D3 concentrations in 
lean individuals in response to 30 minutes cycling exercise. This increased circulating 25(OH)
D3 was observed immediately post-exercise and even persisted for 24 hours. Therefore, 
whether exercise has an effect on 25(OH)D3 and 1.25(OH)2D3 concentrations – potentially via 
improved intracellular metabolism (e.g. hydroxylation) and mobilization of adipose tissue-
derived vitamin D warrants further investigation. 
 Another type of intervention that induces lipolysis is weight loss induced via caloric 
restriction in lifestyle interventions (40). Recently, a 1-year  lifestyle intervention in obese 
individuals resulted in a 26% increase in circulating 25(OH)D3 along with a 26% decrease 
in VAT and 18% decrease in SAT volume (37). This increased 25(OH)D level correlated 
inversely with changes in both SAT and VAT (37). Furthermore,  an increased expression of 
the catabolizing enzyme CYP24A1 was observed in SAT of obese individuals following weight 
loss (25). As CYP24A1 degrades both 25(OH)D3 and 1.25(OH)2D3 (41), this may suggest a 
higher turnover of both 25OHD3 and 1.25(OH)2D3 following weight loss. Further research 
is needed to understand vitamin D dynamics (uptake and release) across different adipose 
tissue depots and under physiological challenges like weight loss and exercise.
Vitamin D and insulin sensitivity
 Data from literatures regarding the effect of vitamin D supplementation on insulin 
sensitivity and glucose homeostasis are still inconsistent as reviewed in chapter 2. The 
majority of these meta-analyses have used a surrogate marker of insulin sensitivity such us 
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HOMA-IR. In chapter 6, we conducted a systematic review and meta-analysis to determine 
the effect of vitamin D supplementation on insulin sensitivity in individuals with or at risk of 
insulin resistance. 
 As reviewed in chapter 2, mainly in vitro and animal data suggest a potential 
role of vitamin D in insulin-sensitive organs. In adipose tissue, vitamin D may affect lipid 
metabolism (42) and may reduce inflammation (43). Vitamin D may affect pancreatic 
insulin secretion via an immunometabolic protection of beta-cells (44) as well as calcium-
dependent mechanisms (45). In addition, it has been demonstrated that vitamin D affects 
skeletal muscle substrate and energy metabolism, insulin sensitivity and lipid composition 
(46, 47). More importantly, skeletal muscle affects 70-90% of postprandial glucose disposal 
and is therefore a key organ in in the regulation of glucose homeostasis and whole body 
insulin sensitivity. 
 Thus, increasing circulating vitamin D concentration by means of supplementation 
might be expected to have beneficial effects during fasting and postprandial conditions 
by improving skeletal muscle glucose handling/insulin sensitivity. However, in chapter 
6, despite the fact that in all supplementation studies increased concentrations of 
serum vitamin D 25(OH)D were observed, our meta-analysis indicated no evidence that 
supplementation with vitamin D has a beneficial effect on peripheral insulin sensitivity, 
as determined by hyperinsulinemic euglycemic clamp, the Matsuda or insulin sensitivity 
index nor on postprandial glucose levels. Furthermore, when we also take into account the 
3 papers that were published since we complete our meta–analysis in 2019  (48-50) (that 
met our inclusion criteria and used a clamp), the results do not change (chapter 6). Thus, 
although mechanistic evidence of vitamin D on glucose responsiveness, insulin receptor 
substrate (20) and insulin sensitivity (47), muscle mitochondria biogenesis (46) as well as 
lipid metabolism (47) have been documented at the transcriptional and post-translational 
level in vitro, our analysis indicate that these do not translate into beneficial functional in 
vivo effect on peripheral insulin sensitivity and postprandial glucose concentrations. 
 It might be argued that the participants from included studies (chapter 6) were not 
deficient enough to observe any major effects of vitamin D supplementation. In chapter 6, 
the mean serum vitamin D 25(OH)D concentrations at baseline varied from 19.2 nmol/L to 
59.9 nmol/L in vitamin D-supplemented groups and 16.9 nmol/L to 61.4 in placebo groups. 
Currently, there is a major discussion on the cut-off point for vitamin D deficiency. Circulating 
25(OH)D3 concentration < 25/30 nmol/L or 25–50 nmol/L are defined as severe deficient or 
deficient (51-53), whereas circulating 25(OH)D3 concentration between 50 to 75 nmol/L and 
> 75 nmol/L are considered as sufficient (52-55). However, the Endocrine Society defines 
vitamin D sufficient when circulating 25(OH)D3 levels > 75 nmol/L (51).
 When we re-analyzed 9 out of 18 studies with mean baseline serum vitamin D 
levels ≤30 nmol/L, the outcome remains unchanged, suggesting no evidence that vitamin 
D supplementation improves peripheral insulin sensitivity in individuals with a low vitamin 
D status. Most (but not all) RCTs included in our meta-analysis recruited participants with 
BMI ≥ 25 kg/m2 and almost all RCTs administrated vitamin D3 as supplementation. It has 
been suggested that large quantities of vitamin D3 may potentially be stored in body fat, 
and are only slowly released as vitamin D 25(OH)D3 (29). In these particular individuals, 
weight loss has been shown to increase 25(OH)D3 levels (25, 37), and potentially increases 
the availability of vitamin D 25(OH)D3 for muscle tissue. Therefore, combining vitamin D3 
supplementation and weight loss in relation to effects on peripheral insulin sensitivity may 
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warrant further investigation in more detail. 
The VDR gene expression, genetic variants and obesity-insulin resistance
 In chapter 2, we reviewed that there is strong evidence that vitamin D affects adipose 
tissue function via its transcription factor VDR, although the effects may vary between 
species and cell models used (56, 57). In chapter 4, we observed that higher abdominal 
SAT VDR gene expression was associated with a reduced AT insulin sensitivity independent 
of BMI, age, sex, and explained 14% of the variance in AT insulin sensitivity. Recent cross 
sectional data, showed that BMI (32, 58) and HOMA-IR (58, 59) are positively associated 
with subcutaneous adipose tissue VDR gene expression. This relationship of higher VDR in 
AT and obesity might be a primary (genetic) defect or more secondary to the obese insulin 
resistant state and mediated by several factors, including vitamin D status and low-grade 
inflammation. Vitamin D 25(OH)D3 deficiency/insufficiency might lead to an inflammatory 
process (60, 61) which could subsequently promote VDR expression. Of interest, in vitro 
data reported that the inflammatory factor TNF-alpha can increase expression and activity 
of VDR in keratinocytes (62), indicating that VDR levels in abdominal SAT may be elevated 
in response to obesity-associated adipose tissue inflammation. However this needs to be 
investigated in more detail in human adipocytes. 
 Polymorphisms in the VDR gene, namely, TaqI, BsmI, ApaI, and FokI, have been 
identified and may be associated with VDR activity and human obesity (63). In chapter 5, we 
investigated whether genetic variants of VDR are associated with obesity phenotypes in the 
DiOGenes study, a Pan-European multicenter, randomized, controlled dietary intervention 
study (64). In chapter 5, we showed that variants in VDR TaqI and ApaI are associated with 
elevated BMI, (contributing 0.9 kg/m2 per risk allele), WC (3 cm per risk allele) or FM (2 kg 
per risk allele) at baseline. In concordance with these results, the VDR TaqI was associated 
with a higher risk of obesity in Greek individuals with BMI <30 and ≥30 kg/m2 (contributing 3 
kg/m2 per risk allele) (65). Our results are in line with some (65-67), but not all studies (68, 69) 
and discrepancies between studies may be partly explained by individuals’ characteristics 
(including differences in the range in BMI, WC, FM, sex, ethnicity).
 In chapter 5, we also investigated whether VDR genetic variants are associated 
with tissue-specific IR and abdominal SAT gene expression (VDR gene and genes related 
AT remodeling, lipid metabolism, and inflammation). VDR polymorphisms were not 
associated with hepatic nor muscle insulin sensitivity index at baseline.  However, the FokI 
VDR polymorphism was associated with adipose tissue insulin resistance (Adipo-IR) as well 
as elevated circulating FFA (contributing 79 µmol/L per risk allele) at baseline (chapter 5). 
In line a recent meta-analysis showed that VDR polymorphisms may be associated with 
insulin resistance (i.e. HOMA-IR) only in Asian and dark-pigmented Caucasian but not in 
white Caucasian (70), which may suggest ethnic-differences. Currently, it is unclear whether 
the association between FokI variants and Adipo-IR or FFA is related to circulating vitamin D 
concentration or vitamin D status, which warrants further investigation. 
 Furthermore, our eQTL analysis observed no major effect of VDR SNP variants on 
abdominal SAT VDR or VDR target gene transcription (chapter 5). This may suggest that VDR 
genetic variants are not a major determinant of VDR gene expression within abdominal SAT 
of overweight/obese individuals as observed in chapter 4. Finally, in chapter 5 we also did 
not find any effects of VDR variants on body weight change, and tissue-specific IR indices 
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following weight loss and weight maintenance, suggesting that the VDR genetic variants may 
not relate to dietary intervention outcome. Of interest, the FokI polymorphism is located on 
the exon in the coding region of the VDR gene, resulting in different translation initiation 
sites (TIS) and giving rise to a full-length VDR protein or a three amino acid shorter VDR 
protein variant (71), having higher transcriptional activity (72, 73). Therefore, future studies 
need to investigate how these VDR variants affect functional VDR activity in human adipose 
tissue and other insulin sensitive tissues such as gut, liver and muscle. 
 Interestingly, a recent GWAS study in two independent cohorts has shown that 
genetic variation in VDR (rs7974353) is associated with overall microbial ß diversity (74). 
Further analysis indicated that Parabacteroides (phylum Bacteroidetes) and unclassified 
Enterococcaceae (phylum Firmicutes) were significantly correlated with the VDR gene 
expression in the gut enterocytes (74). The fact that VDR is highly expressed in intestinal 
tissue (mainly in enterocytes) (75), and that gut microbiota do not express VDR may suggest 
an indirect relationship between vitamin D, VDR expression and gut microbiota composition, 
which warrants further investigation.
Main outcomes of this thesis and future perspectives
 The following gives an overview of the main outcomes of this thesis as well as 
several perspectives for future research,
1. We showed that BMI was inversely associated with vitamin D 25(OH)D3 
concentrations which could not be explained by alterations in abdominal 
SAT vitamin D-metabolizing enzymes. In the present study, plasma vitamin 
D metabolites [25(OH)D3 and 1,25(OH)2D3] were not related to hepatic, 
muscle, and adipose tissue insulin sensitivity. These data suggest that BMI 
but not insulin resistance is the main determinant of vitamin D 25(OH)D3 
concentrations in obesity (chapter 4).
2. A blunted catecholamine-mediated lipolysis was accompanied with a 
decreased 1,25(OH)2D3 but not vitamin D 25(OH)D3 release across abdominal 
SAT in obese men, but did not affect circulating 1,25(OH)2D3 concentration in 
obese men (chapter 3). Additionally, VDR expression in abdominal SAT was 
positively associated with BMI indicating an increased VDR expression in 
obesity (chapter 4). Whether a blunted 1,25(OH)2D3 release might be linked 
with an increased VDR expression in obese SAT still needs further investigation. 
Of interest, we showed that abdominal SAT VDR expression is negatively 
associated with AT insulin sensitivity (chapter 4). Whether this is a primary 
defect or more a secondary phenomenon of the obese insulin resistant state 
(e.g. low-grade inflammation) needs to be investigated in future research. 
3. The VDR polymorphisms are unlikely to play a primary role in tissue-specific 
insulin resistance (chapter 5). However, VDR polymorphisms were associated 
with markers of adiposity including BMI, WC and FM. Of interest, a recent 
study from an Asian population (76) demonstrated that VDR polymorphisms, 
the fat mass and the obesity-associated FTO gene affected weight-loss 
following 6-months dietary and exercise intervention, indicating that VDR 
polymorphisms may interact with other gene polymorphisms in determining 
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intervention-induced weight loss. Therefore, whether and how VDR genetic 
variants in combination with other risk alleles affect lifestyle intervention-
induced weight loss needs further investigation.
4. Our systematic review and meta-analysis from RCTs (conducted between 
1980 - 2019 year) using Matsuda Index, Insulin sensitivity Index, and gold 
standard hyperinsulinemic euglycemic clamp showed no effect of vitamin D 
supplementation on insulin sensitivity or postprandial glucose metabolism in 
individuals with or at risk of insulin resistance (chapter 6). 
 However, it is possible that vitamin D supplementation may have a beneficial 
effect on other cardiometabolic risk factor like low-grade inflammation. Recent 
systematic reviews and meta-analyses (77, 78) reported small, but significant, 
decreases in high-sensitivity C-reactive protein (hs-CRP) and Tumor Necrosis 
Factor alpha (TNF-α) concentrations following vitamin D supplementation. It 
has been shown recently from a Mendelian Randomization study, that hs-CRP 
is one of 4 inflammatory biomarkers in 3 independent clusters (ILs, adhesion 
molecules, acute-phase proteins) which was inversely associated with serum 
25(OH)D3 concentration (79). Further studies are warranted  to investigate 
whether vitamin D supplementation may have beneficial effects on obesity-
related inflammatory markers or might be beneficial in the prevention and 
treatment of immune-related disease like cancer  and inflammatory bowel 
disease (IBD) (80, 81). In line, It has been recently suggested that vitamin D 
may also link to the gut metabolism relating to local gut inflammation and 
gut microbiota composition (82). A recent RCT suggested that vitamin D plays 
a role in maintaining the intestinal permeability and reducing systemic CRP 
concentrations (83). Further, there appears to be a bi-directional interplay 
between the gut microbiota, vitamin D and intestinal inflammation (84). The 
available evidence suggests that the gut microbiome is responsive to both 
vitamin D deficiency and/or supplementation. However, the precise nature 
of the mechanisms in the context of obesity related metabolic disorders is 
unclear and further investigations are warranted.
 Finally, recent findings suggest that the effect of vitamin D supplementation 
on metabolic health may be affected by VDR genetic variants (85, 86). Several 
studies also indicate beneficial effects on metabolic health by combining 
vitamin D supplementation and other modes of intervention such as lifestyle-
induced weight loss (i.e. diet and exercise) (87-89). Therefore, further studies 
with more personalized (sub-group, i.e. carrier and non-carriers of VDR SNPs) 
approaches and combining vitamin D supplementation with other modes 
of intervention might provide new strategies towards a more personalized 
approach for treatment and prevention of insulin resistance in humans.
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Summary
 Currently, the global prevalence of obesity has doubled over decades across socio-
economic and demographic status. At the same time, vitamin D insufficiency and deficiency 
are major public health issue worldwide, where the prevalence of vitamin D deficiency was 
estimated high in obesity regardless of ethnicity, age and sex. Evidence from observational 
studies suggests a negative correlation between body mass index (BMI) and circulating 
vitamin D 25(OH)D3 levels. Up to now, the vitamin D status in the general population is 
based on circulating vitamin D 25(OH)D3 (inactive metabolite) concentrations. Furthermore, 
vitamin D deficiency has also been reported to relate to whole-body insulin resistance. Of 
note, the development of insulin resistance is caused by a complex inter-organ crosstalk, 
including several insulin sensitive tissues such as the liver, the skeletal muscle, and the 
adipose tissue (AT). In this thesis, we aimed to investigate the link between vitamin D status 
and (tissue-specific) insulin sensitivity in human obesity.
Chapter 2 provides an extensive literature review of studies that have examined 
the effects of vitamin D on glucose and lipid metabolism, as well as inflammation in insulin 
sensitive tissues such as the liver, skeletal muscle, AT, pancreas, and the gastro-intestinal 
tract. The majority of the data about the effects of vitamin D in these tissues were derived 
from animal or in vitro studies, with often inconsistent findings. From human observational 
studies, more evidence supports the association between vitamin D and obesity-related 
insulin resistance. However, from human randomized clinical trials (RCTs), evidence for a 
causal role is debatable. Most of RCTs used surrogate markers such as Homeostatic model 
assessment of insulin resistance (HOMA-IR) to define insulin resistance and did not take 
into account ethnic differences. Based on our extensive literature review we concluded that 
vitamin D deficiency may be associated with obesity through several mechanisms including 
sequestration in the AT, an impaired vitamin D related metabolism within AT, and a blunted 
release of vitamin D from AT. However, the link between vitamin D with (tissue-specific) 
insulin sensitivity warrants further investigation, using more standardized (state-of-the-art) 
methodologies such as hyperinsulinemic-euglycemic clamps or insulin sensitivity indices 
derived from an OGTT.
Sequestration of vitamin D metabolites in the excessive amount of AT in conditions 
of increased adiposity is one of the mechanisms that may explain the low circulating vitamin 
D 25(OH)D3 levels in human obesity. Vitamin D is a fat-soluble vitamin, and ex vivo evidence 
from obese AT donors suggests that vitamin D release from the AT obese is blunted following 
lipolytic stimulation with adrenaline. Therefore, we hypothesized that in human obesity 
the often observed blunted catecholamine-mediated lipolysis coincides with a blunted 
release of vitamin D metabolites in vivo. Therefore, in chapter 3, we analyzed vitamin D 
(inactive) 25(OH)D3 and (active)1.25(OH)2D3 fluxes across the abdominal subcutaneous 
adipose tissue (SAT) of obese compared to lean men, in relation to changes in circulating 
vitamin D levels and local AT lipolysis. We observed that both net glycerol release (marker of 
lipolysis) and net release of the active vitamin D metabolite 1,25(OH)2D3 across abdominal 
SAT during ß-adrenergic stimulation were significantly reduced in obese as compared to 
lean men, suggesting a blunted vitamin D 1,25(OH)2D3 release and an impaired lipolysis 
across abdominal SAT in obese men in vivo. In contrast, no significant release of the inactive 
vitamin D metabolite 25(OH)D3 across SAT was observed in lean or obese men following an 
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overnight fast or during ß-adrenergic stimulation, possibly indicating an impaired AT vitamin 
D metabolism (hydroxylation of 25(OH)D3) in human obesity. Total adipose tissue mass may 
be an important determinant of circulating vitamin D levels as it has been proposed that a 
sequestration of vitamin D in the expanded adipose tissue mass may be a responsible factor 
for the vitamin D deficiency in obesity. Additionally, an altered vitamin D metabolism in AT 
may also contribute to vitamin D deficiency and insulin resistance. 
In chapter 4, we investigated (1) whether obesity (BMI) is related to circulating 
vitamin D levels (active, inactive and ratio), and whether alterations in plasma vitamin D 
metabolites may be mediated by an altered AT expression of VDR or vitamin D-metabolizing 
(hydroxylation) enzymes; (2) whether plasma vitamin D and AT expression of VDR relates to 
tissue-specific (adipose tissue, liver and skeletal muscle) insulin sensitivity determined by 
a 2–step hyperinsulinemic-euglycemic clamp with a [6,6-2H2]-glucose tracer; (3) Finally, we 
investigated whether an altered AT vitamin D metabolism may relate to AT insulin sensitivity. 
We demonstrated that (1) BMI was negatively associated with of plasma 25(OH)D3 but not 
with plasma 1,25(OH)2D3, nor its ratio; (2) Plasma vitamin D 25(OH)D3 deficiency was neither 
related to changes in SAT vitamin D-metabolizing enzymes nor SAT VDR gene expression; 
(3) plasma 25(OH)D3, 1,25(OH)2D3, and the active/inactive metabolite ratio were not 
significantly associated with hepatic, peripheral or AT insulin sensitivity; (4) Interestingly, 
SAT VDR gene expression was negatively associated with AT insulin sensitivity (as indicated 
by % suppression of systemic FFA). Therefore, future studies are needed to unravel the 
molecular mechanisms by which nuclear and membrane-bound VDR interacts with insulin 
action and lipolysis in abdominal SAT.
Twin and familial studies from past decades have demonstrated a nontrivial 
heritability of both obesity and circulating vitamin D concentrations. Moreover, several 
large-scale genome-wide association studies (GWAS) have discovered associations with key 
vitamin D enzymes and serum levels of vitamin D. Therefore, we hypothesized that VDR 
genetic variants may be associated with adiposity, whole body insulin resistance and the 
development of T2D. However, whether these VDR variants may also affect AT vitamin D 
metabolism and human SAT at the transcriptional level is unknown. In chapter 5, we tested 
the hypothesis that VDR genetic variants are associated with obesity phenotypes, tissue-
specific insulin resistance and changes in the SAT transcriptome. Therefore, we included 
553 overweight/obesity men and women from DiOGenes study, a multi-center, randomized 
double-blind controlled dietary intervention trial in 8 European countries. We estimated 
hepatic insulin resistance (HIRI) and muscle insulin sensitivity (MISI) using insulin and 
glucose concentrations from a 5 time-points oral glucose tolerance test (OGTT) and adipose 
tissue insulin resistance (Adipo-IR) from fasting insulin and free fatty acids levels. We found 
that TaqI and ApaI genetic variants were associated with markers of adiposity including BMI, 
WC, and Fat Mass. However, the VDR genetic variants were not associated with HIRI or 
MISI. Variants in FokI VDR were associated with Adipo-IR as well as elevated circulating 
FFA. However, cis and trans eQTL analysis demonstrated no major effects of these VDR 
polymorphisms on the SAT transcriptome, indicating that the putative mechanisms of action 
remain to be determined. The VDR polymorphisms did not relate to changes in body weight 
and insulin resistance as result of the dietary intervention.
Several plausible mechanisms to explain a potential role of vitamin D in improving 
insulin sensitivity have been described in chapter 2, including its effects on skeletal muscle 
substrate metabolism, insulin sensitivity and lipid composition. Importantly, the skeletal 
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muscle is recognized as key organ in peripheral insulin sensitivity as it affects 70-90% of 
total glucose disposal under postprandial conditions (non-fasting conditions). Based on the 
conclusions derived from our review in chapter 2, we conducted a systematic review and 
meta-analysis on the effect of vitamin D supplementation on insulin sensitivity in individuals 
with or at risk of insulin resistance (Chapter 6). We systematically searched and performed a 
meta-analysis from studies (published between 1980 and 2018) that met the PICOS (Patients/
participants, Intervention, Comparison/control group, Outcome, and Study Design) criteria: 
(1) study was a randomized controlled trial; (2) study population consisted of individuals 
with elevated (risk for) insulin resistance (overweight, obesity, prediabetes, polycystic ovary 
syndrome (PCOS), and type 2 diabetes without complications); (3) participants were ≥ 18 
years; (4) interventions were vitamin D supplementation vs the appropriate placebo; (5) 
vitamin D supplementation dose was daily, weekly, or monthly; (6) trial length was ≥ 2 
months; (7) serum 25(OH)D level was measured; (8) insulin sensitivity was measured by 
Matsuda index derived from an OGTT and/or insulin sensitivity index derived from IVGTT, 
or by a hyperinsulinemic-euglycemic clamp at the beginning and at the end of the trial. This 
systematic review (chapter 6) provides no evidence that supplementation with vitamin D has 
a beneficial effect on peripheral insulin sensitivity, as determined by the hyperinsulinemic-
euglycemic clamp, the Matsuda or insulin sensitivity index, and postprandial glucose 
concentrations after an OGTT in people with, or at risk for insulin resistance. 
In conclusion, we found that BMI but not insulin sensitivity (in the liver, muscle, or 
adipose tissue) is the main determinant of circulating vitamin D 25(OH)D3 concentration. 
However, the VDR gene expression in abdominal SAT is associated with adipose tissue insulin 
sensitivity, Whether this is a primary defect or more a secondary phenomenon of the obese 
insulin resistant state (e.g. chronic low-grade inflammation) needs to be investigated in future 
research. Furthermore, a blunted vitamin D 1,25(OH)2D3 release and an impaired lipolysis 
across abdominal SAT in obese men was observed in vivo following ß-adrenergic stimulation. 
Further studies are still needed to investigate whether this impaired release of vitamin D 
1,25(OH)2D3 might be linked with changes in the VDR expression in abdominal SAT of obese 
individuals or possibly due to an impaired AT vitamin D metabolism (i.e. hydroxylation) in 
human obesity. In addition, The VDR polymorphisms are unlikely to play a primary role in 
tissue-specific insulin resistance. Finally, our meta-analysis showed no effect of vitamin D 
supplementation on insulin sensitivity or postprandial glucose metabolism in individuals with 
or at risk of insulin resistance. Nevertheless, it is possible that vitamin D supplementation 
may have a beneficial effect on other cardio-metabolic risk factor like chronic low-grade 
inflammation and may have beneficial effects on gut microbiota composition/diversity and 
intestinal health. Further studies with more specific approaches by taking into account 
genetic variations of the VDR and combining vitamin D supplementation with other modes 
of intervention might provide new strategies towards a more personalized approaches for 
treatment and prevention of insulin resistance in humans. 
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 Prevalensi obesitas di dunia telah berlipat ganda tanpa memandang status sosial-
ekonomi dan demografis. Pada saat yang sama, kekurangan vitamin D juga merupakan 
masalah kesehatan masyarakat. Prevalensi kekurangan vitamin D diperkirakan tinggi pada 
orang dengan obesitas tanpa memandang etnis, usia dan jenis kelamin. Bukti dari studi 
observasional menunjukkan korelasi negatif antara indeks massa tubuh (IMT) dan kadar 
vitamin D 25(OH)D3 darah. Kekurangan vitamin D juga dilaporkan berhubungan dengan 
resistensi insulin. Perkembangan resistensi insulin dapat terjadi secara spesifik di beberapa 
organ yang sensitif terhadap insulin seperti hati, otot, dan jaringan adiposa. Dalam tesis ini, 
kami bertujuan untuk menyelidiki hubungan antara status vitamin D dan sensitivitas insulin 
yang spesifik (di otot, hati, dan adiposa) pada orang yang obesitas.
Bab 2 berisi tinjauan literatur yang luas mengenai berbagai studi yang telah 
meneliti efek vitamin D pada metabolisme glukosa dan lemak, serta inflamasi pada organ 
yang sensitif terhadap insulin seperti hati, otot, adiposa, pankreas, dan saluran pencernaan. 
Sebagian besar data-data tersebut berasal dari studi pada hewan coba atau studi in vitro 
(menggunakan sel model), dengan temuan yang tidak konsisten. Dari studi pengamatan di 
manusia, terdapat cukup bukti yang mendukung hubungan antara vitamin D dan resistensi 
insulin terkait obesitas. Akan tetapi, dari uji klinis acak pada manusia (randomized control 
trial/RCT), peran vitamin D terhadap resistensi insulin masih diperdebatkan. Sebagian besar 
RCT menggunakan biomarker tidak langsung seperti penilaian model homeostasis resistensi 
insulin (HOMA-IR) untuk menentukan resistensi insulin. Berdasarkan tinjauan literatur 
kami yang luas, kami menyimpulkan bahwa kekurangan vitamin D mungkin dapat dikaitkan 
dengan obesitas melalui beberapa mekanisme termasuk sekuestrasi vitamin D di jaringan 
adiposa, gangguan metabolisme vitamin D di jaringan adiposa, dan gangguan/hambatan 
pelepasan vitamin D dari jaringan adiposa. Namun, hubungan antara vitamin D dengan 
sensitivitas insulin yang spesifik (di jaringan adiposa, otot, dan hati) memerlukan investigasi 
lebih lanjut, menggunakan metodologi yang lebih terstandarisasi (mutakhir) seperti teknik 
hyperinsulinemic-euglycemic clamp atau indeks sensitivitas insulin yang berasal dari 
beberapa tahap pengambilan glukosa darah setelah tes oral cairan glukosa (oral glucose 
tolerance test).
Sekuestrasi vitamin D metabolit dalam jumlah berlebihan di adiposa yang terjadi 
seiring peningkatan adipositas (penumpukan jaringan lemak/adiposa) diduga menjadi 
salah satu mekanisme yang dapat menjelaskan rendahnya sirkulasi vitamin D 25(OH)D3 
pada obesitas. Vitamin D adalah vitamin yang larut dalam lemak, dan studi ex vivo dari 
jaringan adiposa laki-laki pendonor yang obesitas menunjukkan bahwa terjadi hambatan 
pelepasan vitamin D setelah distimulasi dengan adrenalin. Kami menduga bahwa pada 
secara in vivo, orang yang obesitas mengalami gangguan pelepasan lemak yang dimediasi 
katekolamin, bersamaan dengan itu juga terjadi hambatan pelepasan vitamin D metabolit 
dari jaringan adiposa. Dalam bab 3, kami menganalisis vitamin D 25(OH)D3 dan 1,25(OH)2D3 
fluks dari jaringan adiposa subkutan di bagian perut laki-laki yang obesitas dibandingkan 
dengan laki-laki normal. Kami mengamati bahwa pelepasan gliserol (salah satu penanda 
proses pelepasan lemak/lipolisis) dan pelepasan vitamin D 1,25(OH)2D3 dari jaringan 
adiposa subktan selama stimulasi beta agonis isoprenaline secara signifikan lebih rendah 
pada laki-laki yang obesitas dibandingkan dengan laki-laki normal, mengindikasikan terjadi 
544591-L-bw-Pramono
Processed on: 28-7-2020 PDF page: 148
APPENDIX
Ringkasan
148
A
PP
EN
DI
X
hambatan pelepasan lemak dan vitamin D 1,25(OH)2D3 pada obesitas. Sebaliknya, tidak 
ada pelepasan signifikan dari metabolit vitamin D 25(OH)D3 dari jaringan adiposa subkutan 
di bagian perut pada laki-laki obesitas atau normal, setelah puasa semalam atau selama 
stimulasi beta agonis isoprenaline. Hal ini mungkin mengindikasikan gangguan metabolisme 
vitamin D (hidroksilasi 25(OH)D3) di jaringan adiposa pada orang yang obesitas. Total massa 
jaringan adiposa mungkin merupakan determinan penting dari kadar vitamin D darah, dan 
mungkin merupakan faktor yang bertanggung jawab atas defisiensi vitamin D pada obesitas. 
Gangguan metabolisme vitamin D pada obesitas mungkin juga berkontribusi terhadap 
defisiensi vitamin D dan resistensi insulin. 
 Dalam bab 4, kami menyelidiki (1) apakah obesitas (dilihat dari Indeks Massa 
Tubuh/IMT) terkait dengan sirkulasi kadar vitamin D (metabolit yang aktif, tidak aktif dan 
rasionya), dan apakah perubahan kadar vitamin D dimediasi oleh ekspresi gen enzim-
enzim dalam metabolism vitamin D serta reseptor vitamin D; (2) apakah kadar vitamin D 
tubuh dan ekspresi gen enzim-enzim vitamin D serta gen reseptor vitamin D di jaringan 
adipose berhubungan dengan sensitivitas insulin di berbagai jaringan (jaringan adiposa, 
hati, dan otot). Sensitivitas insulin di jaringan spesifik tersebut diukur dengan teknik gold 
standard hyperinsulinemic-euglycemic clamp dengan pelacak radio-isotop glukosa yang 
stabil [6,6-2H2]-glukosa; (3) Kami juga menyelidiki apakah enzim-enzim metabolisme vitamin 
D di jaringan adiposa juga berhubungan dengan sensitivitas insulin yang spesifik di hati, 
otot, dan jaringan adiposa. Kami menunjukkan bahwa (1) IMT berhubungan negatif dengan 
kadar 25(OH)D3 tetapi tidak dengan vitamin D 1,25(OH)2D3, atau rasionya; (2) Kekurangan 
vitamin D 25(OH)D3 tidak berhubungan dengan ekspresi gen enzim-enzim metabolisme 
vitamin D atau ekspresi gen reseptor vitamin D; (3) Kadar vitamin D 25(OH)D3, 1, 25(OH) 
2D3, dan rasionya tidak berhubungan dengan sensitivitas insulin yang spesifik di hati, otot, 
atau jaringan adiposa; (4) Menariknya, ekspresi gen reseptor vitamin D berhubungan 
negatif dengan sensitivitas insulin di jaringan adiposa. Oleh karena itu, studi yang lebih 
detail diperlukan untuk mengungkap mekanisme molekuler bagaimana reseptor vitamin D 
berinteraksi dengan aksi insulin, serta pemecahan lemak khususnya di jaringan adiposa.
Studi genetik, dari beberapa dekade terakhir telah menunjukkan heritabilitas 
nontrivial dari obesitas dan konsentrasi vitamin D. Selain itu, beberapa studi asosiasi genomik 
skala besar (GWAS) menunjukkan hubungan dengan variasi genetic dari enzim-enzim vitamin 
D dan kadar vitamin D darah. Oleh karena itu, kami berhipotesis bahwa variasi genetik 
reseptor vitamin D mungkin juga berhubungan dengan adipositas, resistensi insulin seluruh 
tubuh serta diabetes tipe 2. Namun, apakah variasi reseptor vitamin D ini mempengaruhi 
transkripsi berbagai gen di jaringan adiposa pada manusia belum diketahui. Dalam bab 5, 
kami menguji hipotesis bahwa varian genetik reseptor vitamin D terkait dengan obesitas, 
resistensi insulin yang spesifik di hati, otot, dan jaringan adiposa, serta mempengaruhi 
transkripsi genetik di jaringan adiposa dari bagian abdomen (perut). Kami menganalisis 553 
pria dan wanita yang kelebihan berat badan / obesitas dari studi DiOGenes, sebuah studi 
klinis intervensi diet di 8 negara Eropa. Kami menganalisis resistensi insulin di hati (hepatic 
insulin resistance index/HIRI) dan sensitivitas insulin di otot (muscle insulin sensitivity index/
MISI) berdasarkan konsentrasi insulin dan glukosa dari uji toleransi glukosa oral (OGTT) 5 
titik waktu (0, 30, 60, 90, 120 menit) serta resistensi insulin jaringan adiposa (adipose tissue 
insulin resistance index/Adipo-IR) berdasarkan kadar insulin puasa dan asam lemak bebas 
dalam darah puasa. Kami menemukan bahwa varian genetik TaqI dan ApaI berhubungan 
dengan marker adipositas termasuk IMT, lingkar pinggang, dan massa lemak. Tidak ada 
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varian genetik reseptor vitamin D yang berhubungan dengan HIRI atau MISI. Varian genetik 
FokI resptor vitamin D berhubungan dengan Adipo-IR serta peningkatan kadar asam lemak 
bebas. Namun, analisis cis- dan trans- eQTL tidak menunjukkan ada pengaruh dari variasi 
genetik reseptor vitamin D ini pada transkripsi genetik di jaringan adiposa, menunjukkan 
bahwa mekanisme keterkaitan varian genetik reseptor vitamin D dengan resistensi insulin 
di jaringan adiposa masih harus diteliti lebih lanjut. Pada studi kami, variasi genetik reseptor 
vitamin D juga tidak berhubungan dengan perubahan berat badan dan resistensi insulin 
setelah di intervensi diet.
Beberapa mekanisme mungkin dapat menjelaskan potensi vitamin D dalam 
meningkatkan sensitivitas insulin telah dijelaskan pada Bab 2, termasuk efeknya pada 
aksi reseptor insulin, komposisi lemak, dan metabolisme di jaringan otot. Lebih utamanya 
adalah otot merupakan organ kunci dalam sensitivitas insulin di jaringan tepi (perifer) 
karena mempengaruhi 70-90% dari total penggunaan glukosa di bawah kondisi postprandial 
(kondisi non-puasa). Berdasarkan ulasan kami di Bab 2, kami melakukan tinjauan sistematis 
dan meta-analisis tentang efek suplementasi vitamin D pada sensitivitas insulin pada 
individu dengan atau berisiko resistansi insulin (Bab 6). Kami secara sistematis mencari dan 
melakukan meta-analisis dari studi (diterbitkan antara 1980 dan 2018) yang memenuhi 
kriteria PICOS (Patients/ pasien/peserta penelitian, Intervention/intervensi yang diberikan, 
Control/kelompok pembanding/plasebo, Outcomes/hasil/luaran yang diukur, dan Study 
design/desain penelitian) kriteria: (1) desain studi adalah RCT; (2) populasi penelitian terdiri 
dari individu dengan/berisiko resistensi insulin (obesitas, prediabetes, sindrom ovarium 
polikistik (PCOS), dan diabetes tipe 2 tanpa komplikasi); (3) pasien berusia ≥ 18 tahun; (4) 
intervensi adalah suplementasi vitamin D vs plasebo yang sesuai; (5) dosis suplemen vitamin 
D adalah harian, mingguan, atau bulanan; (6) lama studi adalah ≥ 2 bulan; (7) kadar vitamin 
D 25(OH)D diukur; (8) sensitivitas insulin diukur dengan indeks Matsuda yang berasal dari 
OGTT atau indeks sensitivitas insulin yang berasal dari tes toleransi glukosa intravenous 
(IVGTT), atau hyperinsulinemic-euglycemic clamp di awal dan di akhir percobaan. Tinjauan 
sistematis dan meta analisis ini (bab 6) menunjukkan tidak ada efek suplementasi vitamin 
D terhadap sensitivitas insulin, yang diukur oleh metode gold standard hyperinsulinemic-
euglycemic clamp, indeks Matsuda atau indeks sensitivitas insulin, serta tidak berefek 
menurunkan konsentrasi glukosa postprandial setelah OGTT pada orang dengan/berisiko 
mengalami resistensi insulin.
Sebagai kesimpulan, kami menemukan bahwa IMT (bukan sensitivitas insulin di 
hati, otot, atau jaringan adiposa) merupakan determinan utama kadar vitamin D 25(OH)D3. 
Selanjutnya, ekspresi gen reseptor vitamin D pada jaringan adipose subkutan berhubungan 
dengan sensitivitas insulin di jaringan adiposa, Perlu diteliti lebih lanjut apakah kaitan 
tersebut merupakan gangguan primer atau lebih merupakan fenomena sekunder dari 
keadaan resisten insulin pada orang obesitas (misalnya sebagai akibat peradangan kronis 
tingkat rendah). Terjadi hambatan pelepasan vitamin D 1,25(OH)2D3 dan gangguan lipolisis 
pada jaringan adipose subkutan pada laki-laki obesitas secara in vivo setelah stimulasi 
katekolamin. Penelitian lebih lanjut masih diperlukan untuk menyelidiki apakah hambatan 
pelepasan vitamin D 1,25(OH)2D3 ini mungkin terkait dengan perubahan ekspresi reseptor 
vitamin D pada jaringan adiposa subkutan pada obesitas atau mungkin karena gangguan 
metabolisme vitamin D pada obesitas. Kemudian, variasi genetik reseptor vitamin D tidak 
berperan utama dalam resistensi insulin di jaringan hati, adiposa dan otot. Pada meta-
analisis, tidak ada efek suplementasi vitamin D terhadap sensitivitas insulin atau penurunan 
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kadar glukosa postprandial pada individu dengan atau berisiko resistansi insulin. Namun, 
suplementasi vitamin D mungkin memiliki efek terhadap faktor risiko kardio-metabolik 
lainnya seperti kemungkinan menurunkan peradangan kronis dan mungkin memiliki efek 
terhadap keanekaragaman mikrobiota usus serta kesehatan intestinal (usus). Studi lebih 
lanjut dengan pendekatan yang lebih spesifik dengan mempertimbangkan variasi genetik 
metabolisme vitamin D dan kombinasi berbagai intervensi mungkin memberikan strategi 
baru menuju pendekatan yang lebih personal untuk pencegahan resistensi insulin pada 
manusia.
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Valorization
Obesity prevalence is increasing worldwide and often coincides with circulating 
vitamin D deficiency and whole-body insulin resistance. The present thesis describes how 
obesity-related phenotypes, vitamin D concentrations as well as vitamin D-related genes 
link to insulin resistance. The valorization potential of the work described in this thesis will 
be discussed in terms of societal and economic relevance, the implications for the scientific 
community and health care professionals, activities/products, including future planning and 
realization.
Societal and Economic Relevance
 
 Obesity is associated with type 2 diabetes mellitus, cardiovascular diseases (mainly 
heart disease and stroke), diabetes, musculoskeletal disorders (especially osteoarthritis – a 
highly disabling degenerative disease of the joints), some types of cancers, depression and a 
reduced quality of life (1), and more recently it was identified as a major risk factor for fatal 
COVID-19 (2). Obesity is a chronic metabolic disorder resulting from an energy imbalance, 
by which a long-term positive energy balance leads to the storage of excess energy as body 
fat (3). Furthermore, obesity is often characterized with vitamin D deficiency. Putative 
mechanisms, linking obesity, vitamin D, and insulin resistance are described in this thesis, 
including obesity, vitamin D deficiency, adipose tissue dysfunction, and tissue-specific insulin 
sensitivity.
 Our study showed that the prevalence of vitamin D 25(OH)D3 deficiency [based 
on Endocrine Society cut-off value < 50 nmol/L] in our study was about 45.7%, and BMI is 
the main determinant of vitamin D 25(OH)D3 concentration in individuals with overweight/
obesity (chapter 4), indicating that obesity-associated vitamin D deficiency could be 
recognized as an important public health concern. Ensuring sufficient circulating vitamin D 
25(OH)D3 level is essential to maintain general health but also may be of importance in the 
management of obesity, and the prevention of insulin resistance and T2D.  
 Oral and intravenous vitamin D supplementation have been suggested to effectively 
increase circulating vitamin D 25(OH)D3 level. Our meta-analysis showed that vitamin D 
supplementation is an effective means to increase circulating vitamin D 25(OH)D3 level, 
despite substantial heterogeneity (chapter 6). However, more research is needed to study 
the efficacy and bioavailability of different types (and routes of administration) of vitamin D 
supplementation to more effectively increase serum vitamin D levels in overweight/obesity. 
 We did not find any associations between circulating vitamin D levels with hepatic, 
muscle, and adipose tissue insulin sensitivity assessed by hyperinsulinemic-euglycemic 
clamp (chapter 4). Furthermore, our meta-analysis showed no beneficial effect of vitamin D 
supplementation on the improvement of insulin sensitivity (chapter 6), suggesting no direct 
causality between vitamin D deficiency and whole body and tissue specific insulin resistance 
in human obesity. 
 Our study using arterio-venous difference techniques across abdominal sub-
cutaneous adipose tissue (SAT) showed that there was an impaired release of active vitamin 
D metabolite in obese men (chapter 3). In addition, we observed that VDR expression in 
abdominal SAT is increased in obesity and associated with adipose tissue insulin sensitivity 
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(chapter 4). This may suggest that adipose tissue may be a key target organ to improve 
vitamin D metabolism in the context of human obesity. Furthermore, currently a project 
on exercise-mediated Vitamin D mobilization sequestered in the human adipose tissue 
(Vita-DEx project) is ongoing (4). If exercise might be beneficial to mobilize vitamin D from 
adipose, then this may have implications regarding the management/treatment of a low 
vitamin D status in obesity.
Scientific Community
  The content of the chapters in this thesis have been presented at national scientific 
meetings (i.e. NASO spring meeting and ADDRM meeting) and international conferences 
(The 25th and 26th European Congress on Obesity). The results have also been discussed 
to health professionals and colleagues inside and outside the scientific community with 
the purpose to discuss the medical and societal consequences of obesity and vitamin D 
deficiency. Moreover, the studies described in this thesis have been published or will become 
available to the scientific community through publication in peer-reviewed journals.
 The findings presented in this thesis, may be of value for health care professionals 
(e.g. physicians and dieticians). Given that fact that the incidence of vitamin D deficiency is 
considerable high (>40%) among obese individuals, this may possibly have consequences 
for recommended nutritional intake. However, a recent RCT reported 750 g/week of 
salmon was not sufficient to prevent a decrease in serum 25-hydroxyvitamin D [25(OH)
D3] in autumn in South-Western Norway in adults with overweight/obesity (5). These data 
suggest that increasing vitamin D intake from diet only, may not be adequate to improve 
circulating vitamin D 25(OH)D3 level in obese individuals. Furthermore, although Vitamin 
D supplementation increased circulating vitamin D levels 25(OH)D3 levels, nevertheless, 
this did not translate to improved whole-body insulin sensitivity (chapter 6). Therefore, 
a combination mode of interventions (e.g. exercise and nutrition) and more personalized 
strategies should be explored in future research. 
 
Activities/Products and Innovation
In this thesis, we combined state-of-the-art methodology including: hyper-
insulinemic-euglycemic clamp, adipose tissue gene expression using qRT-PCR , plasma 
vitamin D and vitamin D fluxes analysis using gold standard LC/MS-MS measurement, 
adipose tissue blood flow  measurements (i.e. xenon washout technique), arterio-venous 
balance technique, PCR-based genetic variant analysis in combination with subcutaneous 
adipose tissue transcriptomic, which together gave important insights in  obesity related 
vitamin D metabolism. Furthermore, we have also conducted a systematic review and 
meta-analysis in this thesis, providing one of the highest levels of evidence in human clinical 
research to date.
Planning and Realization
 
The causal relationship between vitamin D and obesity related metabolic health is still under 
debate. Although, from studies described in this thesis, the direct link between vitamin D 
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and overall metabolic health (non-skeletal function) may not be mediated by tissue-specific 
insulin signaling/sensitivity pathways. However, the link between Vitamin D and metabolic 
health may be partly mediated via its effects on gut microbiota composition/diversity and 
gut health (6). This is supported by the presence of VDR expression in human enterocytes 
and from a recent genome wide association study that suggests a potential link between VDR 
variants and gut microbiota diversity (7). However, future studies are needed to investigate 
in more detail the relationship between vitamin D, gut microbiota, gut health, and its effects 
on host metabolic health.
 Results from this thesis should encourage future Vitamin D research, for instance, 
how genetic variants (chapter 5) in vitamin D metabolisms (VDR and CYP) may influence 
the metabolic outcome of vitamin D supplementation. This will pave the way for studies 
with more personalized (sub-group, i.e. carrier and non-carriers of VDR SNPs) approaches. 
In addition, combining vitamin D supplementation with other modes of intervention (i.e. 
exercise / dietary intervention induced weight loss) might provide new strategies towards a 
more personalized approach for obesity related vitamin D deficiency treatment. 
 Last but not least, while obesity has been suggested as one of the major 
comorbidities of covid-19 (2), vitamin D deficiency is a common feature in obesity, and 
may also be a determinant of covid-19 outcome. More studies warrant to explore the link 
between vitamin D deficiency, obesity, and covid-19 which is highly relevant given the 
current pandemic our society and scientific community is dealing with. 
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